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ABSTRACT
Adult multipotent stromal cells (MSCs) have become popular within veterinary
sciences for direct administration and tissue regeneration due to their differentiation,
trophic and immunosuppressive properties. However, current isolation and expansion
techniques provide a heterogeneous population with other types of cells, which may
affect the efficiency and efficacy of treatments.

The progenitor properties and

function need to be further evaluated in vitro prior to in vivo application. The first
part of this dissertation was to identify the optimal MSC source for general canine
orthopedic applications such as intra-articular injection and joint tissue regeneration.
Based on side-by-side comparisons of cell doublings, colony forming unit frequencies,
target gene expression and immunophenotype, the infrapatellar fat pad (IFP) had
MSCs

with

higher

yield,

expansion,

multipotentiality

and

progenitor

immunophenotypes than joint capsular and cranial cruciate ligament (CrCL)
synovium. The second part of this dissertation was designed for optimization of
isolation and in vitro expansion techniques for feline adipose-derived MSCs (ASCs).
A new method was designed with which a therapeutic dose of ASCs (7 x 106 cells/kg)
was available within 3 cell passages from epididymal adipose excised during
castration.

The isolated ASCs maintained their progenitor properties after

cryopreservation.

Feline-specific culture medium to induce adipogenesis,

osteogenesis and chondrogenesis was also developed in the study for later application
in feline tissue regeneration studies. The third part of this dissertation to apply canine
IFP ASCs for CrCL regeneration. A custom perfusion bioreactor was designed and
built to accommodate canine CrCL templates on which to grow viable grafts with IFP
ASCs. Culture medium and template composition and design were optimized to
induce the ASCs into fibroblasts to form a collagenous ligament. Compared to ASC

	
  

x

	
  
templates cultured in stromal (basal) medium those cultured in induction medium had
enhanced collagen deposition, procollagen synthesis and ligament specific gene
mRNA levels. The results from this investigation confirm the feasibility of growing
new canine CrCLs from ASCs in the laboratory for implantation to treat dogs with
CrCL disruption.

Overall, the investigations in this dissertation provide vital

translational information for canine and feline MSC therapies, and may contribute to
better efficiency and efficacy of in vivo treatment and tissue regeneration.
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CHAPTER 1. STROMAL CELL RESEARCH
1.1 Stromal Cell Introduction
1.1.1 Multipotent Stromal Cell Nomenclature
Stromal (Stem) cells are functional units that are capable of self-renewal through
mitotic cell division and have the potential to differentiate into different cell lineages.
The term stromal was first proposed by Edmund Beecher Wilson in 1896 [1]. Over
70 years later, Canadian scientists Ernest A. McCulloch and James E. Till confirmed
the existence of self-renewing cells from mouse bone marrow [2, 3]. Friedenstein and
his colleagues then discovered that bone marrow-derived cells were able to
differentiate towards osteogenesis [4]. The initial adherent cells expanded in vitro
into round-shaped colonies of fibroblastoid cells or colony forming unit-fibroblasts
(CFU-f). During that same time period, several groups found that bone or bone
extracts formed cartilage or bone after subcutaneous or intramuscular implantation [57]. In the 1970s, bone marrow-derived cells were shown to have proliferative abilities,
specific phenotypic characteristics and to differentiate into adipocytes, chondrocytes
and even myoblasts in vitro [8-11]. Additionally, they were capable of differentiating
into non-mesenchymal lineages such as neurons. Though differentiated cells did not
generate action potentials, this confirmed the plasticity of MSCs [12-14]. Caplan
proposed the name mesenchymal stem cells (MSCs) for the cells isolated from stroma
based on their ability to differentiate into cells within mesenchymal lineages[15].
However, there is intense debate over whether or not the cells should be considered
true stem cells. As a result, the term “multipotent mesenchymal stromal cells” has
been proposed to replace “mesenchymal stem cells” [16, 17].
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1.1.2 Multipotent Stromal Cell Definition and Identification
The term MSC refers to a heterogeneous cell population. The International Society
for Cell Therapy defines an MSC as a cell with the following properties: adherence to
plastic under standard culture conditions; CD73+, CD90+, CD105+, CD34-, CD45-,
HLA-DR-, CD14- or CD11b-, CD79a- or CD19-; and in vitro osteogenesis,
adipogenesis and chondrogenesis (demonstrated by staining) [18, 19]. However,
these criteria are not applied uniformly across species [20].
So far, MSCs have been isolated from numerous species including humans,
dogs and cats, and from many tissues including bone marrow, adipose, cartilage and
synovium [21-25].

Cells derived from different sources show different in vitro

phenotypic characteristics and proliferation, but they share the ability to differentiate
into mesenchymal lineages and surface marker expression [26-28]. Variability in cell
characterization influences the ability to translate uniform MSC-based products into
clinical practice. Uniform definitions and quality control standards are needed to
predict in vivo behavior of implanted cells [29].
1.2 Multipotent Stromal Cell Characteristics
1.2.1 Multipotent Stromal Cell Niche
The stromal cell niche is the complex, three-dimensional (3D) microenvironment
where adult stromal cells reside [30, 31]. The interactions between stromal cells with
the other cells and extra-cellular matrix (ECM) within the niche are complex.
Paracrine interactions occur though growth factors, chemokines and cytokines, among
other factors [31]. Cell-cell interactions occur through cell associated proteins like
cadherins and notch ligands. Interactions with the ECM are possible with proteins
like fibronectin, laminin, collagen and proteoglycan. Other things that contribute to
MSC regulation in the niche include ions, hormones and substrate biomechanical
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properties and architecture. A combination of genetic expression and environmental
signals are required for MSCs give up their ‘stemness’ and go through lineagespecific progenitor division toward terminal differentiation into effector cells [32].
Reconstruction of a functional niche is a critical component of regenerative medicine.
1.2.2 Multipotent Stromal Cell and Pericytes
The exact location and specific role of native MSCs within host tissue is not well
defined. There are few reports surrounding in vivo MSC niches with the exception of
the hair follicle, intestine, synovium and bone marrow [33-36]. In vitro conditions do
not fully replicate the natural niche, which makes it difficult to study. Under ex vivo
culture conditions, MSCs are known to undergo phenotypic alterations that may not
occur in vivo [23]. The perivascular location has recently been suggested as an MSC
niche in human [37, 38]. Pericytes, thought to be progenitor cells, are located on the
abluminal side of small blood vessels, including arterioles, capillaries, and venules in
multiple human organs, including skeletal muscle, pancreas, adipose tissue and
placenta [38].

They are closely associated with endothelia cells and appear to

function similarly to MSCs [39].

They have a similar cell phenotype and

immunophenotype (CD146+, CD34-, CD45- and CD56-) to MSCs and are capable of
osteogenesis, adipogenesis and chondrogenesis in vitro [38, 40-42].

Distinct

similarities have been shown between in situ and in vitro properties of MSCs and
pericytes [43].
The perivascular niche is unlikely to be the only MSC niche [38]. Avascular
tissues like cartilage also contain MSCs [44]. Hematopoietic stromal cells (HSCs) are
believed to have at least two niches, the endosteal niche on the surface of trabeculae;
and the perivascular niche within bone marrow sinusoids [45]. Ways to identify and
recreate MSC niches in vitro remain a vital part of MSC investigations.
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1.3 Therapeutic Effects of Multipotent Stromal Cells
1.3.1 Trophic Effects of Multipotent Stromal Cells
Tissue MSCs are thought to replace cells lost to age, disease or trauma. They are also
known to have a paracrine effect, production of local bioactive factors. The MSC
production of cytokines and growth factors is reported to be relatively constant among
different donors and not influenced by age or health status [46]. However, the
bioactive factors produced by MSCs are affected by differentiation and the local
environment [46].

Effects of these factors can be direct, inducing intracellular

signaling, indirect, stimulating other cells in the vicinity to secret other bioactive
factors, or both. The indirect activity is referred as trophic, since the MSCs do not
differentiate themselves, but their bioactive factor secretion mediates cell behavior.
Some trophic effects include local immune suppression, enhancing angiogenesis,
inhibiting apoptosis and fibrosis and inducing differentiation and mitosis of tissuespecific and tissue-intrinsic progenitors [46].
Exogenous MSCs have been shown to contribute to tissue repair by homing to
damaged tissue where they secrete paracrine and autocrine signals to influence local
cellular dynamics. This effect has been shown in spinal cord injury, myocardial
infarction, meniscus, cartilage and bone repair and Crohn’s disease [28, 47-49].
Chopp et al showed that rat marrow MSCs promote intrinsic neural progenitor cells to
regenerate functional neurological pathways in damaged brain tissue when applied
directly or systemically.

Notably, the exogenous cells do not differentiate into

neurons or neuronal support cells to mediate the effect [47, 50].
1.3.2 Immunomodulatory Effects of Multipotent Stromal Cells
The

MSCs

play

multiple

roles

in

immunomodulation.

The

immunosuppressive effect of MSCs allows them to be used for allogeneic
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transplantation [51]. By definition, major histocompatibility complex (MHC) class I
proteins are expressed by MSCs while MHC class II proteins are not [52, 53].
However, this characteristic is influenced by the microenvironment. The MHC II
expression can be either upregulated or downregulated by IFN-γ [54-57]. Therefore,
the immunosuppressive effect of MSCs is independent of MHC-I and II expression.
The MSCs modulate the functions of the major immune cells including T, B cells,
natural killer (NK) cells, monocytes and dendritic cells (DC). They suppress T-cell
proliferation, cytotoxic T lymphocyte formation and IFN-γ production, thus inducing
the expansion of Treg cells [58-61].

MSCs also inhibit B cell proliferation,

differentiation, chemotactic functions and IgG secretion [62-64]. Additionally, they
inhibit NK cell proliferation, NK cell-mediated cytolysis and NK cell production of
IFN-γ [65]. They also inhibit both DC maturation and activation, and differentiation
of monocytes to DCs, thus increasing T cell anergy [66]. Thus, MSCs are currently
being used to reduce immunological rejection [51].
The MSC immunosuppressive function is mediated by soluble factors, since
cellular communication is not contact-dependent [51, 67]. Several factors have been
found in co-culture systems of immune cells and MSCs (human and murine BMSCs,
placenta and dental pulp MSCs), such as stem cell factor, interleukin (IL)-1β, IL-6,
IL-8, IL-10, IL-12, IFN-γ, transforming growth factor-β1, vascular endothelial growth
factor (VEGF), prostaglandin E2, macrophage colony-stimulating factor, hepatocyte
growth factor and indoleamine 2,3-dioxygenase [65, 68-71]. However, mechanisms
of how MSCs interact with immune cells are still unclear. Research of this issue is
crucial for safe and effective use of MSCs.
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1.3.3 Multipotent Stromal Cell Homing
MSCs have been found localized in inflamed tissue. Up to 100 times more MSCs are
found in the synovial fluid patients with ligament injury compared to healthy donors
[72]. Additionally, compared to non-injured mice, an increased amount of circulating
BMSCs are observed in peripheral blood from mice with intimal hyperplasia [73].
The arrest of MSCs within the vascular system of a tissue followed by transmigration
across the endothelium is called homing [74]. It is a prerequisite for MSCs to
function, particularly when MSCs are administered by systemic infusion. Homing
requires a multistep process with adhesive and signaling events, including adhesion to
the endothelium, transendothelial migration, chemotaxis, matrix degradation and
invasion and in situ differentiation [74, 75]. The mechanisms of MSC homing are not
fully understood, but preliminary studies show that MSCs share at least some features
with homing of leukocytes to sites of inflammation [76]. Initially, cells are rolled on
the endothelium by selectins, which are expressed in inflamed venules [77]. This
process allows cytokines to activate MSCs and stimulates the cells toexpress high
affinity integrins to help them adhere to the vascular endothelium of the target site
[78]. Then, cells migrate transendothelially and invade into ECM by integrin-ECM
molecules interactions and matrix degradation [79, 80].
Numerous chemokines are reportedly involved in the recruitment of MSCs to
the target tissue. For example, the upregulation of stromal cell derived factor-1
enhances murine BMSC and endothelial progenitor cell homing and incorporation
into ischemic tissues [76, 80]. Interleukin 8 and its cellular receptors also contribute
to homing of intravenous infused human CD34+ progenitor cells to ischemic
myocardium in rats [81]. Vascular endothelial growth factor induces bone marrowderived circulating cell recruitment in mice [82].
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Integrins such as integrin-β1,

	
  
integrin α4β1, E- and P-selectin are also involved in recruiting BMSCs, endothelial
progenitor cells in target tissues like tumor, hind limb ischemia and myocardial
infraction [83-88]. These factors may be further used to attract MSCs to specific
locations in further studies.
Culture conditions have a significant impact on MSC homing.

Freshly

isolated mouse MSCs have higher homing capacity compared to culture-expanded
populations [89].

Homing receptors like CXC chemokine receptor type 4 are

expressed in stromal vascular fraction cells but not in cultured MSCs [28].
Transendothelial MSC migration is reduced with in vitro passage, potentially due to
production of tissue inhibitor of metalloproteinases-3, a natural MMP inhibitor [90].
Another reason may be loss of surface markers during in vitro culture. Interestingly,
simulation of ischemic environments in vitro or hypoxic preconditioning, seems to
enhance MSC transendothelial migration by upregulation of MSC MMP production
[91, 92]. All of these factors need to be considered to enhance MSC therapy.
1.3.4 Multipotent Stromal Cell Heterogeneity
Differences in MSCs among donors may contribute to differences in clinical trial
outcomes [93]. Different patient donors have different MSC in vitro expansion rates
and differentiation potentials [94]. Results are also influenced by factors such as
donor age and health status, harvest technique, culture methods and plating density.
Plastic adherence selects for a heterogenous MSC population. MSC heterogeneity
seems to be reduced by consistency among isolation and culture procedures and
selection of MSCs based on surface marker expression. There is no single marker
unique to MSCs with which to yield a pure population. So, panels of markers like
CD29, CD44, CD71, CD73, CD90, CD105, CD106, CD120a, CD124, CD146,
CD271, nestin, SSEA1, and SSEA4 are often used to identify and/or isolate MSCs
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[95]. Additionally, genomic transcripts and proteins have been used to identify MSC
amongst hematopoietic, endothelial and periosteal cells and synovial fibroblasts [96].
Use of such techniques does not confirm multipotentiality of an MSC isolate.
A significant percentage of MSCs that were capable of osteogenesis in vitro did not
form heterotopic osseous tissue in vivo [97].
multipotentiality

and

change

Additionally, MSCs lose their

immunophenotype

with

increasing

passage.

Subpopulations of MSCs isolated with different sets of surface markers have different
properties. For example, human BMSCs that are CD271+, W8B2+ and CD56+ have
higher chondrogenic than adipogenic potential [98]. A cellular subset of CD105+low
human ASCs was found to be more osteogenic than CD105+high ASCs both in vitro
and in vivo [99]. These results confirm the importance of identifying characteristics
of different MSC immunophenotypes.
Heterogeneity also exists among MSCs from different tissue sources.

Rat

MSCs derived from epididymal adipose had higher multipotentiality than epicardial
cells in vitro, but their expansion rates were lower [100]. Joint tissue-derived MSCs,
including ASCs and SSCs, displayed significantly higher chondrogenic capacity than
BMSCs in vivo [101]. Additionally, despite similar in vitro capacities, human ASCs
exhibited significantly higher potential to differentiate into muscle cells than
umbilical cord MSCs in vivo [102]. Compared to subcutaneous fat, patellar adipose
from human patients with knee osteoarthritis (OA) have a lower number of capillarylike structures and higher numbers of stromal and alkaline phosphatase CFUs [103].
Questions remain about how disease affects MSCs.

It is not known if

inflammation in the local environment affects MSCs or if they are protected within
their niche.

The BMSCs from iliac crest or tibia/femur in OA patients had

significantly lower in vitro expansion rates and chondrogenic and adipogenic
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capacities than those from patients without OA, but the osteogenic potential was not
affected [104]. In contrast, MSCs isolated from mice with vascular injuries retained
in vitro trilineage differentiation potential up to 10 passages while those from normal
mice MSCs retained the trilineage differentiation property only to passage 1 [73].
There are many possible reasons for variable results from MSCs harvested from
normal versus diseased or injured tissues including type and level of disease, harvest
location, cell types, individual variation, species differences and MSC isolation and
expansion methods. Therefore, in order to identify factors that contribute to different
MSC behavior, variables should be limited as much as possible.
1.3.4 Adipose Derived Multipotent Stromal Cells (ASCs) versus Preadipocytes
ASCs are important to innate immunity and angiogenesis, two properties that are vital
to development of viable tissues derived from them. It is proposed that there are two
types of precursor cells in adipose tissue, preadipocytes with limited differentiation
capacities and ASCs [105]. Compared to ASCs, preadipocytes have a shorter lifespan
and cannot be maintained in vitro for prolonged periods of time [105]. Additionally,
preadipocytes are reported to be CD34+ in contrast to ASCs, the majority of which
are CD34- [18, 19]. Preadipocytes secrete numerous inflammatory cytokines such as
TNF-α and are sensitive to lipopolysaccharide activation [106]. They also have many
proteins in common with monocyte/ macrophages, such as adipocyte protein 2,
peroxisome proliferator-activated receptors-gamma (PPAR-γ), and nicotinamide
adenine dinucleotide phosphate-oxidase [107, 108]. Preadipocytes can also display
phagocytic activity [109, 110]. Macrophage-like properties decline after commitment
of preadipocytes into adipocytes, so they may be limited to adipocyte progenitors
[109].
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Preadipocytes are also have properties of endothelial-like progenitors [111].
Development of a capillary network is required to support optimal tissue function and
remodeling. Human CD34+/CD31- ASCs have been shown to differentiate into an
endothelial phenotype in vitro and in vivo [53]. Additionally, adipogenic lineage
proteins induce potent proangiogenic factors, including monobutyrin, VEGF and
leptin [112-115]. Thus, ASCs may be beneficial in vascular reconstruction during
tissue regeneration.
1.4 Multipotent Stromal Cells in Tissue Engineering
MSCs in combination with scaffolds are often used for tissue engineering. Cellscaffold constructs have the potential to provide a spatial and temporal
microenvironment that mimics the stromal cell niche to support cell proliferation,
regulate cell function and promote tissue regeneration [116].
1.4.1 Cell Sources
Potential MSC sources include fully differentiated, adult cells, adult MSCs,
embryonic stem cells (ESCs) and induced-pluripotent stem cells [117].

Fully

differentiated adult cells have limited proliferation capacity and lifespan both in vitro
and in vivo [118]. Compared to MSCs, ESCs have higher differentiation potential.
However, their application is limited due to ethical issues, potential risk of tumor
formation and immune rejection. Therefore, adult MSCs have become a popular
source in tissue engineering.

There are over 20 tissue sources of adult MSCs.

Historically, the tissue forming capacity of MSCs was thought to be limited to the
mesoderm. However, recent evidence shows that MSCs have greater plasticity (the
capacity to differentiate into cell types from different germ layers) than previously
thought [13]. In fact, under appropriate culture conditions, MSCs are capable of
differentiating into all three germ layers [119, 120]. Though the mechanism of
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transdifferentiation or plasticity is not fully understood, this MSC characteristic has
distinct advantages for tissue engineering.
Cell sources can also be categorized as autologous, allogeneic and xenogeneic
cells. Autologous cells are least likely to undergo immune rejection, since they are
from the same individual body. However, they are not always available, and may not
be viable or expandable in vitro. Harvest of autologous cells may cause donor site
morbidity [121].

In addition, cells may be influenced by diseased conditions.

Allogeneic cells from individuals of the same species and xenogeneic cells from
individuals of different species offer alternatives to this situation [122]. Concerns
surrounding allo- and xenogeneic sources also include disease transmission, infection
and immune rejection [123, 124].
1.4.2 Scaffold Carriers
Extra-cellular matrix varies among tissues [125]. The ECM has five major functions
[126]. It provides structural support and a physical environment so that cells are able
to attach, proliferate, migrate, differentiate and function. It also confers mechanical
properties to the tissue. The ECM provides bioactive cues for regulating the activities
of residing cells.

Finally, the ECM provides a dynamic environment for

vascularization and new tissue formation.

The goal of scaffold synthesis is to

replicate the ECM of the target tissue to give the best chance to recreate it. Scaffolds
should be composed of materials to give it similar physical and mechanical properties
as the native tissue as well as degradation that occurs at the same rate as tissue
generation.

Porosity should be sufficient for nutrient transfer and cell adhesion

without compromising mechanical strength.
Four wide categories of scaffolds designed to carry MSCs include porous
structures, decellularized ECM, confluent cells with ECM, and cells encapsulated in
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hydrogel [126]. Porous structures composed of natural or synthetic biodegradable
and biocompatible materials are one of the most popular approaches to scaffold
carriers. Scaffolds can be designed to mimic hard and soft tissue ECM. The ideal
pore diameter is around 150 µm for hard tissue formation and 200 – 250 µm for soft
tissue formation [124]. Natural ECM that is decellularized has similar composition
and

mechanical

properties

as

native

tissue

ECM.

However,

complete

decellularization is required to minimize immunogenicity, and tissue properties may
be altered by harvest, decellularization and deproteinization [127, 128]. Layers of
sheets of confluent cells within the ECM they produce are typically used to
reconstruct highly cellular tissues like epithelium and endothelium.

Injectable

hydrogel has been applied for cartilage and soft tissue generation with MSCs [129,
130]. Hydrogel formulations can be made with both natural and synthetic materials
by physical and chemical crosslinking [131, 132]. Scaffolds are customized to the
intended in vivo application. Tissue-specific properties and the amount of tissue to be
regenerated are considerations when identifying scaffold carriers.
There are general approaches to prepare MSC-scaffold constructs for
implantation. One is to inject MSCs into scaffolds during surgery [133]. Another
approach is to culture MSC-scaffold constructs in differentiation medium for a period
of time (7-21 days) to induce cell differentiation and tissue specific ECM production
and then implant them orthotopically [134]. Pre-seeding of human BMSCs on the
poly-L lactic acid (PLLA) mesh has higher osteogenic potential in rats compared to
injecting MSCs into the scaffold during surgery [135].

Another approach is to

encapsulate MSC-scaffold constructs within protective coatings and allow cells to
mature in vitro in an orthotopic implantation site.

Oligo(poly(ethylene glycol)

fumarate) hydrogel composites loaded with rabbit BMSCs and TGF-β1 showed
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chondrocyte potential in vitro [136]. Co-encapsulation of TGF-β3 in hyaluronic acid
hydrogels with human BMSCs supports neo-cartilage formation when implanted
subcutaneously in mice [137]. So far, there is no clear agreement about which
approach is better. Specific circumstances should be considered to identify MSCscaffold pre-implantation conditions, including material types of the scaffold, cell
types and types of tissue forming.
1.4.3 Bioreactors for 3-Dimensional Culture
Monolayer culture does not mimic the mechanics and cell-cell or cell-ECM
orientation. Problems associated with 3-D scaffolds include difficulties with gas
exchange and nutrient delivery. Additionally, cell seeding is more difficult in 3-D
scaffolds, and non-homogenous cell distribution can result in non-uniform tissue
formation. A 3-D cell culture system is a natural step between 2D in vitro culture and
in vivo conditions.
Bioreactors are dynamic systems used to load and culture cells on scaffolds
[138]. There are a number of different types of bioreactors including rotating wall
vessels, direct perfusion systems and spinner flasks [138]. Spinner flasks and rotating
wall vessels are normally used to enhance nutrient transport into the porous structure
by rotating the medium [139]. A perfusion system is a more complex setup designed
to direct fluid through the inside of the construct [140].
Perfusion bioreactors provide a more uniform distribution of the medium
within scaffolds compared to spinner flask and rotating vessels, and they provide
mechanical stimulation of cells in the scaffold in the form of shear stress [141]. Shear
stress is critical for cell differentiation and ECM deposition [142].
bioreactors are preferred for orthopedic tissue engineering [143].

Perfusion

The chamber

(cartridge) is customized to hold the scaffold. For optimal cell loading, the chamber
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should approximate the sides of the scaffold. Fluid is moved through the chamber by
a pump.

Common flow rates range from 0.3 – 3.0 ml/min [144].

Perfusion

bioreactors have been shown to increase production of growth factors that contribute
to cell differentiation [145].

Dynamic perfusion culture also helps reduce the

concentration of these factors in the local area and promote differentiation of rat
BMSCs throughout starch-based fiber scaffolds [145]. Production and distribution of
growth factors in vitro may be a benefit of perfusion bioreactors for tissue
regeneration in vivo.

However, perfusion bioreactors require optimization for

targeted tissue production. Cell seeding is crucial for tissue regeneration and is
specific to tissue type. It also ranges widely for a given purpose. For example,
human anterior cruciate ligament regeneration in a bioreactor with BMSCs has been
reported to require between 106 to 108 cells/cm3 [123, 146]. An optimal cell density
should be based on both cell (expansion and differentiation) and tissue (type, density,
matrix deposition) characteristics. Flow rate is another parameter that varies widely
among different scaffold types, cell sources, tissues, and system capacities [123].
Most importantly, more in vivo models should be tested before putting the perfusion
bioreactors into a clinical setting.
1.5 Veterinary MSC Applications
In general, MSC-applications are at very early stage in veterinary medicine. The
mechanism of MSC function in vivo is still not fully understood, and efficacy in vitro
or in preclinical animal studies has not been established.

Perhaps the earliest

application of MSCs in veterinary medicine has been the use of MSCs to treat equine
suspensory ligament desmitis using 20 ~ 60 ml of bone marrow mononuclear cells
[147].

Treatment led to an improvement in athletic function rates compared to

conventional treatment in many studies.
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therapeutic effects were from MSCs, since only 1 in 10,000 - 15,000 cells of
mononuclear cells of bone marraow aspirate are estimated to be MSCs [148]. MSCmediated therapies have been also been applied to dogs to treat tendon, ligament and
cartilage/joint injuries. So far, different cell sources have been used, including the
adipose-derived stromal vascular fraction (SVF) and culture-expanded BMSCs and
ASCs. Compared to culture-expanded cells, SVF require a larger tissue harvest
volume to achieve therapeutic doses. Also, culture-expanded MSCs need to be fully
characterized according to the minimum criteria mentioned above. BMSCs are the
most investigated MSCs in veterinary medicine, and have been characterized in
horses, dogs, and cats, among other domestic species.

They have displayed

comparable expansion rates, differentiation potential and surface marker expression
as human and rat BMSCs. Adipose tissue is another option for MSC harvest with a
500 fold greater number of SVFs [149]. With a treatment of 4.2 ~ 5 x 106 SVF from
adipose, the lameness, pain and range of motion have been significantly improved for
dogs with chronic OA [150]. Both culture-expanded BMSCs and ASCs have been
applied in cats with chronic kidney disease (CKD). In a pilot study, two out of the
four cats administered 1 ~ 4 x 106 ASCs by unilateral intrarenal injection had a
modest increase in glomerular filtration rate along with a mild decrease in serum
creatinine concentration, indicating improved kidney function [151]. This and other
studies emphasize the need for controlled in vitro and in vivo studies as well as
clinical trials.
This dissertation focuses on the clinical translation of MSC-based therapies.
Chapter two is to identify the optimal MSC intra-articular source for general
orthopedic therapies. Applications include direct administration into the joint to treat
osteoarthritis and tissue regeneration of intra-articular tissues, such as cartilage,
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ligaments and tendons. Chapter three discusses a new isolation method of MSCs
from excised feline tissue. The purpose of this study is to collect MSCs without the
need for additional tissue harvest. Compared to canine and equine, MSCs in feline
remain largely unexplored. This study also provides vital information on in vitro
culture, multipotentiality and cryopreservation. As a continuation of chapter two,
chapter four surrounds generation of viable canine cranial cruciate ligament (CrCL)
structures using ASCs and biocompatible scaffolds under custom induction and
perfusion culture conditions. Results of these studies are intended to contribute tto
canine and feline tissue engineering and regenerative medicine.
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CHAPTER 2. CANINE INTRA-ARTICULAR MULTIPOTENT STROMAL
CELLS (MSC) FROM ADIPOSE HAVE THE HIGHEST IN VITRO
EXPANSION RATES, MULTIPOTENTIALITY, AND MSC
IMMUNOPHENOTYPES
2.1 Introduction
Rupture of the cranial cruciate ligament (CrCL) is the leading orthopedic disorder of
the canine stifle [152, 153]. Concomitant intra- and periarticular damage occurs with
70% of CrCL ruptures, and quality of life is reduced by the progressive pain,
dysfunction, and osteoarthritis [154, 155]. Many tissues within the stifle have limited
regenerative and reparative capacities, so surgical intervention is often necessary to
restore joint function [156].

Current surgical options do not necessarily restore

damaged tissues or inhibit joint degeneration [157]. The emerging field of tissue
engineering with adult multipotent stromal cells (MSCs) has significant potential for
generation of viable, functional, engineered stifle tissues to replace those lost to injury
and degeneration [158]. Meanwhile, knee pain is a complaint in as many as 20% of
the general adult population in United States, and more than 20 million people seek
medical attention for knee pain each year [159]. The canine stifle (knee) is an
established large animal model for human knee studies given its similar anatomy
structure and joint kinetics [160]. The model is routinely used to develop and test
surgical procedures, implants, and mechanisms of CrCL treatment and reconstruction
[161, 162].

Additionally, significant preclinical work surrounding isolation,

characterization and therapeutic application of adult MSCs has been done with the
model [163-165].
Ideal cell candidates for intra-articular tissue regeneration should have high
proliferative capacity, produce tissue specific extracellular matrix and survive in the
intra-articular environment [166].

Orthotopic adult stromal cells have greater

commitment to tissue-specific lineages than those from heterotopic sources [167].
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Intra-articular stromal cells have better expansion capacity and potential for stifle
joint tissue regeneration than cells from other sources [168]. Infrapatellar (IFP)
adipose and synovium are established intra-articular MSC sources, and CrCL cell
isolates are reported to have higher expression of ligament specific phenotypic
markers than peri-articular ligaments and tendons [169, 170].

For the potential

benefits of orthotopic stromal cell tissue regeneration to be realized in clinical stifle
therapies, it is critical to identify the optimum intra-articular source of adult MSCs. A
direct comparison of cell isolate phenotypes and their in vitro expansion capacities
and multipotentiality within individuals is key to achieving this goal.
Recently, canine IFP adipose derived multipotent stromal cells (ASCs) were
shown to have greater or equal expansion capacity to bone marrow MSCs and
comparable multipotentiality following cryopreservation [171].

Based on this

information and the stated goal above, we hypothesized that stifle joint MSCs from
IFP (ASC) had higher stromal cell tissue density, in vitro expansion rates,
multipotentiality, and MSC cell immunophenotypes than synovium lining the joint
capsule (SSC) and synovium surrounding the CrCL (LSC) up to cell passage (P) 6.
2.2 Materials and Methods
2.2.1 Ethics Statement
All animal experiments were approved by the LSU Institutional Animal Care and Use
Committee.
2.2.2 Study Design
Synovium lining the joint capsule, IFP, and CrCL were collected from one normal
stifle of six mixed breed female dogs (23.1 ± 0.9 kg, 3.3 ± 0.4 years, mean ± SEM)
undergoing stifle surgeries for reasons unrelated to the investigation. Stifles included
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in the study had no detectable radiographic changes or visible intra-articular
abnormalities. The following assessments were performed on cells from all tissues in
each dog: P0-6 cell doublings (CD) and doubling times (DT); P0, 3 and 6 CD29+,
CD44+, CD90+, CD34+, and CD45+ cell percentages; P0, 3 and 6 fibroblastic,
osteogenic, and adipogenic colony forming unit frequencies; P0 chondrogenic pellet
alcian blue (proteoglycan) staining; P0 and 3 stromal (undifferentiated) and
differentiated (adipogenic, osteogenic, and chondrogenic) cell MSC and lineage
specific target gene mRNA levels. Cell immunophenotypes were also determined in
the stromal vascular fraction (SVF) of pooled tissue harvests collected immediately
post-mortem from both normal stifles of ten adult, female, mixed-breed dogs
euthanized for unrelated reasons. Pooling was necessary for adequate cell numbers,
so only one SVF sample for each cell type was evaluated for nucleated cell density
and with flow cytometry.
2.2.3 Cell Isolation and Expansion
Adipose tissue and joint capsular synovial cells were isolated sterilely according to a
published protocol with minor modifications [171].

Briefly, adipose tissue and

synovium were minced into small pieces, and the CrCL surface was vigorously
lavaged with PBS to detach the synovial membrane. Tissues were then digested with
collagenase solution (DMEM-Ham’s F12 [HyClone, Logan, UT], 0.1% type I
collagenase [Worthington, Biochemical Corporation, NJ], 1% bovine serum albumin).
After 1 hr, the pellet resulting from centrifugation (260 g, 5 min) was resuspended in
stromal medium (DMEM-Ham’s F12, 10% fetal bovine serum [FBS] [HyClone], 1%
antibiotic/antimycotic solution) and filtered (100 µm, BD Falcon, Bedford, MA)
following addition of an equal volume of red cell lysis buffer (0.16 mol/L NH4Cl,
0.01 mol/L KHCO3, 0.01% EDTA). The resulting SVF were seeded in 10 mm dishes
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(CellStar, Greiner, NC) at a density of 5 x 103 cells/cm2 in stromal medium and
cultured under standard conditions (37°C, 5% CO2). Medium was refreshed after 4
hours and then every 2-3 days.

Subsequent passages were performed at 80%

confluence with a cell seeding density of 5 x 103 cells/cm2. For purposes of this study,
primary cell isolates were considered the SVF. The first cell passage of the primary
cells was P0.
2.2.4 Cell Expansion (P0-6)
Cell doublings (CD) and cell doubling time (DT) were determined with duplicate
cultures in 12-well plates at an initial seeding density of 5 x 103 cells/cm2 [172]. Cells
were counted after 2, 4, and 6 days of culture. CD and DT were calculated with the
formulae: CD= ln(Nf /Ni)/ln(2) DT= CT/CD (Ni: initial cell number; Nf: final cell
number; CT=culture time) [173].
2.2.5 Multipotentiality (P0, 3, 6)
Limiting-dilution assays to determine fibroblastic (CFU-F), adipogenic (CFU-Ad),
and osteogenic (CFU-Ob) colony forming unit frequencies [174]. A total of 5 x 103,
2.5 x 103, 1.25 x 103, 6.25 x 102, 3.12 x 102, or 1.56 x 102 cells were placed in each
well of one row (one concentration/row, 8 replicates/concentration) in a 96-well plate.
Cells were cultured in stromal medium for 7 days. Fibroblastic (CFU-F) colonies
were then fixed with 1% paraformaldehyde and stained with 0.1% toluidine blue. For
adipogenesis (CFU-Ad), cells were cultured in stromal medium for 7 days, followed
by

culture

in

adipogenic

medium

(DMEM-Ham’s

F12,

3%

FBS,

1%

antibiotic/antimycotic solution, 33 µmol/L biotin, 17 µmol/L pantothenate, 1 µmol/L
dexamethasone, 100 µmol/L indomethacin, 1 µmol/L insulin, 0.5 mmol/L
isobutylmethylxanthanine [IBMX], and 5 µmol/L rosiglitazone) for 21 days. Wells
were then fixed as above and stained with oil red O. Similarly, osteogenesis wells
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were cultured in stromal medium for 7 days and then cultured in osteogenic medium
(DMEM-Ham’s F12, 10% FBS, 1% antibiotic/antimycotic solution, 10 mmol/L βglycerophosphate, 10 nmol/L dexamethasone, and 50µg/ml sodium 2-phosphate
ascorbate) for 21 days. Colonies were fixed in 70% ETOH and stained with 2%
alizarin red. Wells were considered positive for MSC, adipogenesis, or osteogenesis
when there were ≥10 toluidine blue-stained colonies, ≥10 oil red O-stained colonies,
or ≥1 alizarin red-stained colonies, respectively [175]. The ratio of negative to total
wells in rows (one for each concentration) containing negative wells were used to
estimate the CFU for each concentration using the equation F=e-x (F: ratio of negative
to total wells within a row (concentration), e: natural logarithm constant 2.71, x: CFU
number per well). Based on a Poisson distribution of a clonal cell lineage, the value
of F = 0.37 occurs when the number of total cells plated in a well contains a single
CFU.13,14 The mean value from each plate was used as the CFU for each animal/cell
type/differentiation medium. For chondrogenesis, 2.5 x 105 cells were centrifuged
(200 x g, 5 min) to form a pellet in a 1.5 ml microcentrifuge tube following 7 days of
culture in stromal medium. The pellet was cultured in chondrogenic differentiation
medium (DMEM-Ham’s F12, 3% FBS, 1% antibiotic/antimycotic solution, 50 µg/mL
abscorbate phosphate, 100 nmol/L dexamethasone, 40 µg/mL proline, 2 mmol/L
sodium pyruvate, 1% ITS, and 10 ng/mL TGF- β3) for 21 days with media changes
every 2–3 days. Pellets were formalin-fixed, paraffin-embedded, sectioned (5 µm)
and stained with alcian blue.
2.2.6 Expression of marker genes
Total RNA was isolated from cells (RNAqueous Kit, Ambion, Grand Island, NY),
DNase-treated, and reverse-transcribed using oligo (dT) primers and Moloney murine
leukemia virus reverse transcriptase.
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extracted by homogenization in TRI Reagent (Sigma Aldrich, St Louis, MO). Target
gene mRNA levels were quantified with qRT-PCR using SYBR Green technology
(MJ Research Chromo4 Detector, Bio-Rad Laboratories). Canine-specific primers for
MSC and adipogenic, osteogenic, and chondrogenic lineages were used (Table 1)
[174].

Values were normalized to glyceraldehyde 3-phosphate dehydrogenase

(GAPDH). Relative gene expression was quantified according to 2-ΔΔCt [176].
Table 1 Canine-specific primer sequences for adipogenic, osteogenic, chondrogenic,
and progenitor genes
Primer
Housekeepi GAPD
ng
H
PPARγ
Adipogenic
Leptin
Col1
Osteogenic
OPG
Chondroge
nic

Aggrec
an
Col2
Sox2

MSC
Nanog

Forward Primer

Reverse Primer

TGGCAAAGTGGATATTG
TCG
TTCTCCAGCATTTCCAC
TCC
TGTGTTGAAGCTGTGCC
AAT
GGTGGTGGCTATGACTT
TGG
TGTCTATACTGCAGGCC
GGTG
TTGCACTCAGGAGAGGA
GAC
ACCTCAAGAAGGCCCTG
CTC
CCTGACCTGTTTCGTGA
CCT
AATAACCCGAATTGGAG
CAG

AGATGGACTTCCCGTTG
ATG
AGGCTCCACTTTGATTG
CAC
CCCTCTGTTTGGAGGAG
ACA
CAGTTCTTGGCTGGGAT
GTT
TCAGGCAGAACTCAAGC
TCCA
CCACGCAGGTGGCTCCA
TTC
CCCCACTTACCGGTGTG
TTT
CTATCGCCAGCTCGTAC
TCC
AGCGATTCCTCTTCACA
GTTG

PPAR-γ, peroxisome proliferator-activated receptor gamma; Col1, collagen type I;
OPG, osteoprotegerin; Col2, collagen type II; Sox2, sex determining region Y-box 2;
Nanog, homeobox protein nanog.
2.2.7 Immunophenotype
Cell aliquots (105) were resuspended in 200 ml PBS containing 5 ul antibody. Cells
were incubated with antibodies specific for canine antigens or validated for canine
cross reactivity against PE-CD34, FITC-CD44, PE-CD45, and PE-CD90 for 30 min at
room temperature (Table 2). The cells were then washed with PBS and fixed with 4%
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paraformaldehyde. For non-conjugated CD29 staining, the cells were incubated with
antibody for 30 min at room temperature. They were then incubated with a secondary
antibody, FITC-conjugated goat anti-mouse IgG (Sigma Aldrich) for 30 min, washed
with PBS, and fixed as above. For negative autofluorescence control, cells were not
incubated with antibodies. Cellular fluorescence was evaluated by flow cytometry
using a FACSCalibur flow cytometer and CellQuest Pro software (BD Biosciences,
San Jose, CA). Cell percentages expressing each antigen were determined. Due to
low SVF cell numbers, flow cytometry was performed on representative samples for
each tissue type using pooled cells from unrelated dogs. Pooling was necessary for
adequate cell numbers so only one sample was processed for each antibody.
Table 2 Antibodies against canine MSC surface markers
Antibody Label

Marker
Expression

Cat
No.

Target
Species

CD29

N/A

β1 integrin

610468

Human

CD34

PE

Hematopoietic
(HSC)

559369

Canine

CD44

FITC

Hyaluronic acid receptor

eBiosciences

115440

Canine

CD45

PE

HSC, leukocyte antigen

eBiosciences

125451

Canine

CD90

PE

Thy-1, fibroblasts, MSC,
eBiosciences
HSC

125900

Canine

IgG

FITC

Secondary antibody

F9006

Mouse

Manufacturer
BD
Biosciences
progenitor BD
Biosciences

Sigma-Aldrich

2.2.8 Statistical Analysis
All results are presented as mean ± SEM. ANOVA models (GraphPad Prism, La
Jolla, CA) were used to compare CD, DT, CFU frequency, RNA levels, and cell
surface marker percentages among passages within cell types and among cell types
within passages. Tukey’s post hoc tests were applied for multiple group comparisons
(P<0.05).
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2.3 Results
2.3.1 Cell Harvest
Using pooled samples, 3.4 x 105 nucleated cells/g were isolated from IFP (2 –
3g/stifle), 3.0 x 105 cells/g from synovial membrane (1 – 2g/stifle), and 1.1 x 106
cells/g of CrCL (2.2 x 105 cells/CrCL).
2.3.2 Cell Expansion
Day 2 and day 4 cell counts were used as the initial number to calculate expansion
rates on days 4 and 6, respectively. Differences were not significant between days, so
data was collapsed over this variable. The overall (P0-P6 combined) CD for ASC,
SSC, and LSC were 1.7 ± 0.1, 1.5 ± 0.1, and 1.2 ± 0.1 CD/day, respectively (Table 3).
Table 3 Canine ASC, SSC, and LSC cell doublings (CD/day) for P0-6 (mean ± SEM)
P0

P1

P2

P3

P4

P5

P6

ASC

1.9±0.2 A,a/b

2.0±0.2 A,a/b

2.1±0.2 A,a

1.6±0.2 A,a/b/c

1.8±0.2 A,a/b

1.4±0.6 A,b/c

0.9±0.1 A,d

SSC

1.9±0.2 A,a

1.8±0.2 A,a

1.7±0.2 A,a

1.7±0.2 A,a

1.5±0.2 A,a

1.3±0.1 A,a

0.5±0.1 B,b

LSC

1.5±0.1 A,a/b

1.8±0.1 A,a

1.5±0.2 A,a/b

1.4±0.2 A,a/b

1.1±0.1 B,b/c

0.8±0.1 B,c/d

0.4±0.1 B,d

Columns with different upper-case letters within passages and those with different
lower-case letters within cell types are significantly different from each other
(P<0.05).
The corresponding overall DT (P0-6) were 0.7 ± 0.1, 0.7 ± 0.1, and 0.8 ± 0.1 days/CD
(Table 4). Within cell types, P6 ASC had significantly lower CD than P0, 1, 2, and 4,
and significantly higher DT than P0-4. The P6 SSC had significantly lower CD and
higher DT than all previous passages, and P6 LSC had significantly lower CD and
higher DT than P0-4. There were no significant differences in CD among cell types
for P0-3. For P4-6, LSC CD was significantly lower than ASC. The P5 SSC CD
value was significantly higher than LSC. After P5, SSC and LSC had significantly
higher DT than ASC.
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Table 4 Canine ASC, SSC, and LSC doubling times (days/CD) for P0-6 (mean ±
SEM)
P0

P1

P2

P3

P4

P5

P6

ASC

0.6±0.1A,a

0.6±0.1A,a

0.5±0.0A,a

0.8±0.1 A,a

0.6±0.1 A,a

0.8±0.1 A,a/b

1.2±0.1 A,c

SSC

0.6±0.1 A,a

0.7±0.1 A,a

0.7±0.1 A,a

0.7±0.1 A,a

0.8±0.1 A,a

0.9±0.9 A,a

3.0±0.6 B,b

LSC

0.7±0.1 A,a

0.6±0.1 A,a

0.8±0.1 A,a

0.8±0.1 A,a

1.0±0.1 A,a

1.6±0.2 B,b

3.7±0.6 A,c

Columns with different upper-case letters within passages and those with different
lower-case letters within cell types are significantly different from each other
(P<0.05).
2.3.3 Multipotentiality
All cell types displayed characteristic adipogenic (See A-C in Figure 1), osteogenic
(See D-F in Figure 1), and chondrogenic (See G-H in Figure 1) differentiation. The
CFU frequency indicates the minimum number of cells that includes one capable of
forming a fibroblastic (CFU-F) colony or differentiating into osteogenic (CFU-Ob) or
adipogenic (CFU-Ad) cell lineages. Results were presented as frequencies, so higher
numbers indicate more cells required for a cell with the indicated reduced
differentiation capacity. Due to limited cell expansion past P4, P6 LSC were not
included in CFU assays. Within cell types, the P6 ASC and SSC CFU-F were
significantly higher than P0, and the LSC P3 CFU-Ad was significantly higher than
P0 (Table 5). Among cell types, P0 and P3 LSC had significantly higher CFU-F,
CFU-Ad and CFU-Ob than ASC. The P3 SSC had significantly higher CFU-Ad than
ASC, and P6 SSC had significantly higher CFU-Ad and CFU-Ob than P6 ASC.
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Figure 1 Trilineage differentiation of canine ASCs, SSCs and LSCs
P0 ASC, SSC, and LSC after 21 days culture in adipogenic (A, B and C), osteogenic
(D, E and F), and chondrogenic medium (G, H, and I). Lipid droplets stain red with
Oil Red O, calcified colonies stain red with Alizarin red, and proteoglycans stain blue
with Alcian blue. A stromal cell pellet cultured in stromal medium and stained with
Alcian blue (J) is included for comparison. Original magnification: A-F, 10x, G-J,
63x, scale bar = 600 µm.
Table 5 Colony forming unit frequencies for canine ASC, SSC, and LSC following
fibroblastic (CFU-F), adipogenic (CFU-Ad), or osteogenic (CFU-Ob) induction

CFU-F

CFU-Ad

ASC

SSC

LSC

P0

212.0±45.6A,a

248.3±42.7 A,a

1343.5±170.6 B,a

P3
P6
P0
P3
P6

565.6±104.9A,a
3888.2±747.2 A,b
155.0±58.6 A,a
387.5±88.8 A,a
6602.8±979.8 A,b

919.7±158.9 A,b
7834.7±1892.4 B,c
739.1±157.7 B,a
1528/7±269.1 B,b
9350.0±65.7 B,c

4423.4±871.5 B,b
1570.4±213.6 C,a
4411.4±357.2 C,b

P0
703.6±193.2 A,a
820.6±106.4 A,a
1734.1±196.4 B,a
CFU-Ob
P3
1274.8±302.5 A,a
1596.6±235.6 A,b
3670.8±494.2 B,b
P6
6266.7±945.4A,b
10050.0±1068.9B,c
Columns with different upper-case letters within passages and those with different
lower-case letters within cell types are significantly different from each other
(P<0.05).
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2.3.4 Target Gene Expression
Compared to SSC and LSC at the same passages, induced P0 and P3 ASC had
significantly higher mRNA levels of peroxisome proliferator-activated receptor
gamma (PPAR-γ) and leptin following adipogenic induction, osteoprotegerin (OPG)
and collagen 1 (Col1) following osteogenic induction, and aggrecan following
chondrogenic induction (See A-F in Figure 2). Following adipogenic and osteogenic
induction, P0 and P3 ASC had significantly lower mRNA levels of homeobox protein
nanog (Nanog) than SSC and LSC, and the same was true for sex determining region
Y-box 2 (Sox2) expression following adipogenic induction. There were significantly
lower mRNA levels of Sox2 in P3 ASC compared to LSC and SSC following
osteogenic induction.
2.3.5 Immunophenotype
The majority of P0 and P3 cells were CD29+, CD44+, CD90+, CD34- and CD45(Figure 3), and the SVF of all cell types had lower percentages of CD44+ and CD90+
cells than P0 and 3 (See A-C in Figure 4). The SSC and LSC SVF had higher CD34+
percentages than the ASC SVF (See D in Figure 4). With increasing passages, the
percentages of CD34+, CD29+, CD44+, and CD90+ cells tended to decrease in all cell
types, while the percentages of CD45+ cells remained relatively constant (See E-H in
Figure 4). Among cell types, the P0 ASC CD29+ percentage was significantly higher
than the LSC (See A in Figure 4). The P3 ASC and SSC CD29+ percentages were
significantly higher than LSC, and P6 ASC percentage significantly higher than SSC
(See B in Figure 4). The CD44+ percentage was significantly higher for P3 SSC than
ASC, though the P6 ASC percentage was significantly higher than P6 SSC. The P6
ASC CD90+ percentage was significantly higher than P6 SSC (See C in Figure 4). As
above, due to limited cell expansion, flow cytometry was not performed on P6 LSC.
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2.4 Discussion
Stromal cell-mediated tissue regeneration is a promising approach for a wide range of
medical applications. We have established the IFP as the optimum source of MSC in
the canine stifle among those evaluated. Consistent with the hypothesis, the MSC
population, in vitro expansion rates, and multipotentiality were highest in ASCs
compared to SSCs and LSCs within individuals up to P6 based on cell doublings,
CFU frequencies, MSC immunophenotypes, and target gene expression. As passages
increased, cell doublings, CFU frequencies, MSC immunophenotypes, as well as
MSC, adipogenic and osteogenic lineage-specific gene expression decreased in all
three cell types, suggesting some reduction in MSC numbers and multipotentiality.
Notably, the ASCs retained these characteristics the best through multiple cell
passages.

This information surrounding intra-articular MSCs may contribute to

studies aimed at clinical translation of stromal cell technology.
Most stifle tissues are derived from interzonal mesenchyme, so MSCs derived
from these tissues may share common features which are distinct from those residing
elsewhere [17]. Orthotopic cell sources have advantages for intra-articular tissue
regeneration based on in vitro differentiation studies, possibly a result of exposure to
the local joint environment during development potentiating cell differentiation into
specialized joint tissues [11, 21, 177]. Multipotent cell numbers, expansion capacity
and multipotentiality vary among the different tissues that contain MSCs within the
femorotibial joint such as IFP, synovium, synovial fluid, and CrCL [22, 169]. We
sought to identify and establish the best MSC source for stifle-specific tissue
regeneration by comparing some major intra-articular cell sources within individuals.
The ASC DT in this study was similar to previous reports for canine IFP and
subcutaneous ASCs and human IFP ASCs [178, 179]. The DT for canine SSCs and
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LSCs in this study were significantly lower than that those reported for human SSCs
and LSCs [180]. In addition to species differences, the human LSCs were harvested
from the anterior cruciate ligament (ACL) core minus synovium, collagenase
digestion was not performed and a different culture medium was used.
differences in results between the studies are not unexpected.

Hence,

In this study,

decreasing cell doubling capacity with increasing passages in all cell types suggests
that intra-articular MSCs from early passages may have the best expansion potential
to meet therapeutic needs.
The ASC stromal, osteogenic, and adipogenic CFU frequencies in this study
were higher than previously reported for dogs [174]. Differences may be because of
the use of fresh versus revitalized cells. Indomethacin in the adipogenic medium in
this study may have also contributed to higher CFU-Ad frequencies over the previous
canine study (975.7±125.3) [181]. The higher adipogenic capacity of ASCs may also
be due to a native preadipocyte population in P0 [182]. However, preadipocytes and
multipotent cells are distinguished by the short preadipocyte lifespan in contrast to
high expansion capacity and multipotentiality retained by MSCs through passages, so
preadipocytes are unlikely to have affected later passages [111]. Canine IFP ASCs
have been reported to have similar osteogenic capacity to bone marrow-derived
stromal cells (BMSCs), which supports the superior osteogenesis of the ASCs
compared SSCs and LSCs in this study [174]. Information surrounding direct
comparisons of the chondrogenic potential of stifle joint tissues is limited, but rat
SSCs reportedly have better chondrogenic potential than MSCs from subcutaneous fat
[183]. Additionally, IFP ASCs had better chondrogenic potential than BMSCs and
subcutaneous ASCs in elderly humans with osteoarthritis [184]. Though there was no
difference in proteoglycan staining among intra-articular tissues evaluated in this
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study, higher mRNA levels of Col2 and aggrecan mRNA in ASC pellets may indicate
higher chondrogenic potential.
The identity of the MSC populations within each tissue was confirmed, in part,
by the presence of common MSC cell surface markers detected with flow cytometry.
The mRNA levels of embryonic stromal cell markers previously used to identify
canine MSCs in adult tissue, Nanog and Sox2, also supported the MSC identity of cell
populations isolated from all three intra-articular tissues in this study [24]. Cluster of
differentiation (CD), also called cluster of determinants, are clusters of antigens that
react with antibodies associated with various cell characteristics.

They were

originally used to identify different stages of lymphocyte maturation, but profiling of
CD cell surface antigen expression with flow cytometry is now a standard mechanism
by which MSC phenotypes are distinguished. The CD34+ cells within the SVF are
consistent with human subcutaneous ASCs [185]. Type B synoviocytes (fibroblastlike) are also CD34+ [186]. Since the LSCs were harvested from synovium around
the ligament, it is reasonable that the SVF of LSCs as well as SSCs contained higher
percentages of CD34+ cells. Plastic adherence appeared to effectively select against
CD34+ cells with increasing passages.
The location, size, accessibility, and protective synovial capsule of the IFP
make it a good potential MSC harvest option [174]. It may be feasible to isolate cells
for reapplication prior to closure during standard surgical procedures. Additionally,
cells may be expanded in vitro and banked for later application. The number of
autologous MSC harvested from the synovium or CrCL in a diseased or injured stifle
may be limited since synovium undergoes significant pathogenic changes in the
presence of inflammation, and the CrCL is often partially or completely ruptured in
injured stifles [187]. Despite this, it is feasible that synovium and CrCL may be
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potential MSC sources for tissue-specific engineering since they may contain less
primitive cells than the IFP. Further research is necessary to identify and confirm this
possibility.
The IFP is encapsulated and separated from the joint by synovium [188].
Hence, MSCs niches within the IFP may therefore contain cells that receive less
stimulation to induce differentiation and therefore remain more primitive compared to
other intra-articular niches [179, 189]. Human IFP ASCs from osteoarthritic knees
have comparable long-term cell expansion, multipotentiality, and MSC markerexpression as normal BMSCs [190].

This is distinct from intra-articular SSCs,

BMSCs and cartilage-derived stromal cells, where cell morphology, proliferation, and
multipotentiality are negatively affected by acute and chronic inflammation as well as
the presence of OA [104, 191, 192]. The results of this study suggest that the IFP is
the optimum tissue source for adult MSC isolation in the canine stifle compared to
joint capsular or ACL synovium. The orthotopic advantages as well as the relative
isolation of MSCs within the IFP in the face of injury or disease further supports the
advantages of this tissue source. Study findings are limited to normal tissues, and
additional studies are necessary to confirm them in abnormal joints with distinctions
between those affected by injury versus degenerative changes. In conclusion, this
side by side comparison of canine stifle joint tissue sources establishes the IFP as
having the highest cell density and MSCs with the highest expansion capacity,
multipotentiality, and MSC immunophenotype over multiple cell passages in vitro.
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CHAPTER 3. ISOLATION AND CHARACTERIZATION OF FRESH AND
REVITALIZED MULTIPOTENT CELLS FROM EXCISED FELINE
ADIPOSE
3.1 Introduction
Adult multipotent stromal (stem) cells (MSCs) are gaining popularity in veterinary
medicine due to their differentiation potential, immune privilege, and sustainability in
culture [193]. The therapeutic effects of MSCs are thought to be, in part, due to their
release of trophic and immunomodulatory factors [62, 194]. Of companion animal
species, stromal cell therapy has been applied in dogs and horses, but comparably few
MSC investigations have been performed with cat tissues [150, 195-197]. Most
feline-specific MSC reports surround BMSCs, which are reported to have both
neurogenic and cardiogenic capacities [25, 198-200].

Additionally, intra-renal

injection of BMSCs and ASCs for chronic kidney disease has had promising results
[151]. Feline inguinal ASCs have higher proliferative rates in vitro than BMSCs, one
of the many attributes that make adipose an appealing source of MSCs [201].
In addition to those mentioned above, there are numerous pathological
conditions in the cat that may benefit from ASC therapy. Potential targets include
complications associated with diabetes mellitus, lymphoma, and retinal disease which
affect between 0.2% and 2% cats in the United States [202-205]. There are reports of
canine and human MSC therapies for these conditions at doses of 0.5 to 50 million
MSCs/kg [202-205]. Prior to clinical application, heterogeneous MSC isolates should
be thoroughly characterized to meet a minimum standard of care. At present, there
are few tools to meet the standards of the International Society for Cell Therapy with
feline MSCs [18]. Mechanisms to characterize feline MSCs are necessary for clinical
translation of this novel treatment modality for feline companions.
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Adipose-derived stromal cells can be isolated from both white adipose tissue
(WAT) and brown adipose tissue (BAT). As a highly active metabolic tissue, WAT
contains a large number of stromal vascular cells with great differentiation potential
[206, 207]. Since epididymal adipose harvested during routine feline castration is one
of the purest sources of WAT it is a promising tissue for ASC harvest [208].
According to the 2011-2012 National Pet Owners’ Survey by the American Pet
Products Association, 88% of approximately 86.4 million privately owned cats in the
United States are spayed or neutered. ASCs harvested from tissue excised during
neutering may be expanded in vitro and applied in the short term or cryopreserved for
later application. Based on current information, therapeutic doses of MSCs range
from 105 to 108 cells/kg. The differentiation potential and expansion rate of ASCs
decreases with increasing passages in most species, and the cells tend to have the
highest multipotentiality before P4 [174]. Based on results from other species, 0.5 ~ 2
x 106 nucleated cells can be expanded from one gram of inguinal or epididymal
adipose tissue with a colony forming unit frequency of 1% to 10% [150, 209-211].
Cell doubling times for most species are approximately two days before P4 [174, 212].
Based on broad assumptions from the published literature in other species,
approximately 2 ~ 3 g of feline epididymal adipose would be needed to yield 106
nucleated cells/g containing 104 ASCs to provide a dose of 107 ASCs within three cell
passages.

Our objective was to optimize ASC isolation and expansion so that

therapeutic doses of ASCs can be harvested from individual cats based on the
hypothesis that 107-108 ASCs are available within 3-4 cell passages to give an MSC
treatment dose of 106-107 ASCs/kg from individual cat epididymal ASCs prior to and
after cryopreservation.
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3.2 Methods
3.2.1 Study Design
Epididymal tissue was collected during routine castration of 14 male domestic short
hair cats (1.0 ± 0.2 years, 2.9 ± 0.3 Kg, mean ± SEM). The body conditioning score
of the cats included in this study were around 4 – 6 on a scale of 1 – 9. Cell
expansion rate, multipotentiality and progenitor cell surface markers were evaluated
for both fresh and revitalized (cryopreserved for 1 month) cells from individual cats
as follows: P0-5 cell doublings (CD) and doubling times (DT); P0, 1, 3 and 5 CD29+,
CD44+, CD90+, CD34+, and CD45+ cell percentages; P0, 1, 3 and 5 colony forming
unit (CFU) -fibroblastic (F), adipogenic (Ad) and osteogenic (Ob) frequencies; P1 and
3 stromal and induced (adipogenic, osteogenic, and chondrogenic) cell MSC and
lineage specific target gene mRNA levels. Fresh cells from each cat were further
assessed: P0 chondrogenic pellet alcian blue (proteoglycan) staining; stromal vascular
fraction (SVF), P0, 1 and 3 F-actin and Hoechst dye staining. The SVF CFU-F
frequencies were also determined using pooled tissue from 10 other male domestic
short hair cats to meet adequate cell numbers for seeding.
3.2.2 Materials
All reagents were purchased from Sigma Chemical Co. (St. Louis, MO) or Fisher
Scientific (Dallas, TX) unless noted otherwise.
3.2.3 Isolation Method
Epididymal adipose was harvested, and tissue was processed within 4 hrs of harvest
for each cat. Adipose tissue was isolated with sharp dissection, minced, and digested
in 33 ml Type I collagenase per gram of adipose (Worthington, NJ).
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The isolation method was first discovered using tissues from 5 cats. Tissues
from the rest 9 cats were all digested with the best method. Tissues from each cat
(n=5) were divided into three equal portions, and each portion was digested by one of
three methods: 1) 0.3% type I collagenase in Kreb’s Ringer buffer, 0.5 hr, 1000 rpm
stirring (New); 2) 0.3% type I collagenase in Kreb’s Ringer buffer, 1 hr, 1000 rpm
stirring (Hour); and 3) 0.1% type I collagenase in DMEM, 0.5 hr, 60 rpm (Classic).
The digestion solution was then filtered (100 µm, BD Falcon, Bedford, MA). The
resulting pellet (260 g, 5 min) was resuspended in 5 ml red cell lysis buffer (0.16
mol/L NH4Cl, 0.01 mol/L KHCO3, 0.01% EDTA). The resulting SVF was seeded in
a 10 mm cell culture dish (CellStar, Greiner, NC) in stromal medium (DMEM-Ham’s
F12, 10% fetal bovine serum (FBS), 1% antibiotic/antimycotic solution) and cultured
under standard conditions (37°C, 5% CO2). Medium was refreshed after overnight
incubation and then every 2-3 days. When the first colony that contained > 20 cells
was discovered, the number of colonies was counted. MSC density was calculated as
colony number/adipose weight (g). The new method was selected to isolate ASCs for
the remainder of the study based on the highest number of colonies/g epididymal
adipose. For purposes of this study, primary cell isolates were considered the SVF
and the first cell passage was P0. Cells were seeded at a density of 5 x 103 cells/cm2
for P0 and all subsequent passages for all assays.
3.2.4 Cell Expansion
P0 cells were seeded in 12-well plates and counted after 2, 4, and 6 days of culture.
Cell doublings and DT were determined with duplicate cultures and calculated with
the formulae: CD= ln(Nf /Ni)/ln(2) DT= CT/CD (Ni: initial cell number; Nf: final cell
number; CT=culture time) [172]. Day 2 and day 4 cell counts were used as the initial
number to calculate expansion rates on days 4 and 6, respectively.
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3.2.5 Trilineage Differentiation
Feline-specific induction media were developed in this study. Cells at P0 were first
cultured in stromal medium to 80% confluence, and then transferred to adipogenic
medium (α-MEM, 10% rabbit serum, 10% FBS, 10nM dexamethasone, 5µg/mL
insulin, 50µM 5,8,11,14-eicosatetraynoic acid (ETYA) [Cayman, Ann Arbor, MI],
100µM indomethacin) for 10 days. Cells were fixed with 4% paraformaldehyde (PFA)
and stained with Oil Red O. Confluent P0 cells were also cultured in osteogenic
medium (DMEM, 10% FBS, 100 nM dexamethasone, 0.25 mM L-ascorbic acid) for
10 days and then in osteogenic medium supplemented with 10nM β-glycerophosphate
for another 10 days to avoid delamination. Cells were fixed in 70% ethanol and
stained with 2% alizarin red. For chondrogenesis, 5 x 105 cells were centrifuged (200
x g, 5 min) to form a pellet in a 15 ml tube (Corning, NY). The pellet was cultured in
chondrogenic differentiation medium (Low glucose DMEM-Ham’s F12, 1% FBS, 1%
antibiotic/antimycotic

solution,

50

µg/mL

ascorbate

phosphate,

100

nM

dexamethasone, 40 µg/mL proline, 1 mM sodium pyruvate, 1% ITS, 10 ng/mL BMP6, 10 ng/mL TGF- β1) for 21 days. Cell pellets were cultured in stromal medium for
comparison. At the end of the culture period, pellets were formalin-fixed, paraffinembedded, sectioned (5 µm) and stained with alcian blue.
3.2.6 Multipotentiality (SVF, P0, 3, 6)
Limiting-dilution assays to determine CFU-F, -Ad and -Ob frequencies were
performed as previously reported with changes indicated [174]. Due to the low ASC
density in the SVF, samples were pooled from 10 unrelated cats, and 8 replicates of
500, 250, 125, 63, 31, or 16 cells were seeded for CFU-F. For P0, 1, 3, and 5, 8
replicates of 5 x 103, 2.5 x 103, 1.25 x 103, 6.25 x 102, 3.12 x 102, or 1.56 x 102
cells/well were incubated in a 96-well plate. Cells were cultured in stromal media for
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10 days. The CFU-F colonies were fixed with 4% PFA and stained with 0.1%
toluidine blue. For CFU-Ad and -Ob, cells were cultured in lineage-specific induction
media as described above, and the number of stained colonies in each well was
counted. Wells were considered positive for fibroblast-like colonies, adipogenesis, or
osteogenesis when there were ≥10 toluidine blue-stained colonies, ≥10 oil red Ostained colonies, or ≥1 alizarin red-stained colonies, respectively.

The CFU

frequencies were calculated as F=e-x (F: ratio of negative to total wells within a row, e:
natural logarithm constant 2.71, x: CFU number per well). Based on Poisson’s
distribution, F = 0.37 occurs when the number of total cells plated (N) in a well
contains a single CFU. The CFU frequency is reported as 100 / N %.
3.2.7 Immunophenotypes (P0, 1, 3, 6)
Cell aliquots (105 - 106) were resuspended in 200 ml PBS containing 5 µl of antibody.
Cells were incubated with antibodies specific for feline antigens or validated for feline
cross reactivity for 30 min at room temperature (Table 6). The cells were then
washed with PBS and fixed with 4% PFA. For CD9, CD29, CD44, and CD90
samples, indirect immunofluorescence was done with goat anti-mouse IgG-FITC. For
negative autofluorescence control, cells were not incubated with antibodies. Cellular
fluorescence was evaluated by flow cytometry using a FACSCalibur flow cytometer
and CellQuest Pro software (BD Biosciences). Cell percentages expressing each
antigen were determined using population gated of fluorescence subtracting relative
autofluorescence control.
3.2.8 Cell Morphology (SVF, P0, 1, 3)
Cells were cultured in stromal medium on glass coverslips for 7 days. Cells were
washed with PBS, fixed in 4% PFA for 20 min, permeablized with 0.5% Triton-x100
for 20 min, and stained with Acti-stain™ 488 (1:150) (cytoskeleton, Denver, CO) and
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Hoechst dye (1:2000) for 5min at RT. Samples were then viewed with a fluorescence
microscope DM4500B (Leica, Buffalo Grove, IL).
Table 6 Antibodies for feline ASC Fluorescence-activated cell sorting (FACS)
analysis
Antibo
dy

Label

Target
Species

Manufacturer

Cat No.

Marker Specification

CD9

N/A

Cat

Serotec

MCA1345

Myeloid

CD29

N/A

Human

BD
Biosciences

610468

Cell adhesion, β1 integrin

CD44

N/A

Cat

VMRD

BAG40A

Hyaluronic acid receptor

CD90

N/A

Human

eBiosciences

CD105

PE

Human

eBiosciences

IgG

FITC

Mouse

Sigma-Aldrich

14-090980
12-105741

Endoglin, mesenchymal,
and erythroid progenitors

F9006

Goat anti-mouse IgG

Thy-1, fibroblasts, MSC

3.2.9 Expression of marker genes (P1, 3)
Total RNA was extracted from cells using TRIzol reagent (Fisher) according to the
manufacturer’s

instructions.

Quantity

was

determined

with

a

ND-100

spectrophotometer (NanoDrop Technologies, Wilmington, DE), and 1 µg of RNA was
used for cDNA synthesis per 20 µl reaction using a QuantiTect Reverse Transcription
Kit (Qiagen, Hilden, Germany). Feline-specific primers were used for all reactions
(Table 7). qRT-PCR was performed in duplicate with a 20 µl total reaction using a
QuantiTect SYBR Green PCR Kit (Qiagen), 0.3 µM for each forward and reverse
primer in a 384 well PCR plate. PCR amplication was performed using Applied
BioSystems 7900 Real-Time PCR System (SDS v2.4; Applied Biosystems, Carlsbad,
CA) and stoped at 40 cycles according to the manufacturer’s program. In the present
study, the data are presented as the fold change in target gene expression in
differentiated cells normalized to glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) and relative to the stromal cell control according to 2-ΔΔCt [176].
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Table 7 Feline-specific primer sequences
Gene

Forward Primer

Reverse Primer

GGTCATCCCAGAGCT AGCTTGACAAAGTGG
GAATG
TCATTG
GGGAGTTTCTAAAGA GTCCTCAATGGGCTTC
PPAR-γ
GCCTGAG
ACATTCAGC
Adipogenic
CCATCTTGGACAAAC GTTGAAGCTGTGCCA
Leptin
TCAGGAC
ATCCG
GACAAGGGTGAGACA CTTCTCTTGAGGTGGC
Col1
GGCGAACAG
TGGGG C
Osteogenic
GTCTCATTCGAGAAG CACAACCGCGTGTGC
OPG
AACCC
GAGTGC
GCAGTACACATCATA CATCGTGTTCCATTAC
Aggrecan
GGTCTC
AGAGC
Chondrogenic
CACAGATTATGTCGT
CCAGACGCTGGTGCT
Col2
CGCAGAGGA C
GCTGACGC
GGAGGTACATGCTGA CAGTACAACTCCATG
Sox2
TCATG
ACC
MSC
GATCTCCTCTGCAGA
CTCCAGTGCCTGAGA
Nanog
AGTGG
TTGATGG
PPAR-γ, peroxisome proliferator-activated receptor gamma; Col1, collagen type I;
OPG, osteoprotegerin; Col2, collagen type II; Sox2, sex determining region Y-box 2;
Nanog, homeobox protein nanog.
Housekeeping GAPDH

3.2.10 Statistical Analysis
All results are presented as mean ± SEM. Among passages, differences in CD, DT,
CFU frequency, RNA levels and cell surface marker percentages were determined
with one-way ANOVA and Tukey’s post hoc tests (P<0.05) using SAS.
3.3 Results
3.3.1 Isolation Method
A mean of 0.2 ± 0.03g (wet weight) adipose was harvested from each cat. The Hour
and Classic isolation methods yielded 3.8 and 1.6 colonies/g, respectively, which
were not significantly different. The New isolation method had a higher yield of
126.3 ± 33.9 colonies/g with tissues from five cats (see A in Figure 5). Using tissues
from 14 cats, the mean ASC yield was 76.3 ± 22.2 colonies/g of tissue, which was not

	
  

42

	
  
significantly different that the finding with five cats (see B in Figure 5). At 80%
confluence, there were about 1 x 106 P0 cells per 10 cm dish for P0-2. With a
consistent seeding density of 5 x 103 cells/cm2, around 2 x 107 cells are available by
P2, which is 7 x 106 cells/kg for the cats in this study.

A.

B.250

150

Colonies/g

Colonies/g

250

50
20
10

50
30
15
0

New

C

la
s

sic

r
1h

N

ew

0

150

Figure 5 Feline epididymal adipose ASC isolation method
(A) Feline epididymal adipose ASC yields using three different digestion techniques
(n=5). (B) ASC yield using the new digestion method (n=15).
3.3.2 Cell Morphology
Five days after seeding, adherent SVF cells showed a spindle-shaped morphology
typical of ASCs (see A in Figure 6). Homogenous cultures and elongated shaped cells
increased at P0 and 1 (see B,C in Figure 6), which became flattened and disorganized
by P3 (see D in Figure 6).

Figure 6 Feline ASC morphology
Cells of SVF (A), P0 (B), P1 (C) and P3 (D) were stained with FITC-F-actin (green)
for the microfilaments and Hoechst dye (blue) for the nucleus (20x).
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3.3.3 Cell Expansion
The overall CD for P0-5 fresh cells was 0.7 ± 0.1 CD/days, and the corresponding DT
was 1.4 ± 0.2 days/CD. Generally, cell expansion rates decreased as passages
increased. For fresh cells, P0-2 cells had significantly higher CD than P3-5 (Table 8),
while P0-3 cells had significantly lower DT than P4 and 5 (Table 9). For revitalized
cells, P1 and 2 cells had significantly higher CD than P3-5, and P1-3 cells had
significantly lower DT than P4 and 5. Fresh cells at P4 and 5 had significantly higher
CD and lower DT than revitalized cells.
Table 8 Fresh and revitalized feline ASC cell doublings (CDs/day) for P0-5 (mean ±
SEM)

Fresh

P0

P1

P2

P3

P4

P5

1.3±0.1a

1.1±0.1b

0.9±0.1b

0.5±0.04c

0.3±0.02c

0.3±0.04*,c

1.1±0.1a

0.9±0.1a

0.5±0.03b

0.2±0.02c

0.1±0.01c

Revitalized

Values within columns with asterisks are significantly different from revitalized cells.
Values with different lower-case letters within passages (columns) are significantly
different (p<0.05).
Table 9 Fresh and revitalized feline ASC doubling times (days/CD) for P0-5 (mean ±
SEM)

Fresh
Revitalized

P0

P1

P2

P3

P4

P5

0.8±0.2a

0.9±0.2a

1.1±0.2a

2.0±0.4a

3.3±0.6*,b

3.3±1.2*,b

0.9±0.1a

1.1±0.2a

2.0±0.4a

5.0±1.6b

10.0±1.2c

Values within columns with asterisks are significantly different from revitalized cells.
Values with different lower-case letters within passages (columns) are significantly
different (p<0.05).
3.3.4 Trilineage Differentiation
After about four days of culture in adipogenic medium, cells became round, and, after
21 days, robust lipid droplets were apparent (see A in Figure 7). In osteogenic
medium without β-glycerophosphate, cells assumed a compact, cuboidal appearance
and expressed alkaline phosphatase (ALP) after 10 days of culture (see B in Figure 7).
Following the addition of β-glycerophosphate, granular nodules formed that stained
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with alizarin red (calcium deposition) after 21 days of culture (see C in Figure 7).
Cells were apparent within lacunae in pellets cultured in chondrogenic induction
medium after 21 days, and extra-cellular matrix stained with alcian blue (unsulfated
proteoglycan) (see D in Figure 7). Pellets cultured in stromal medium did not show
lacunae formation (see E in Figure 7).

Figure 7 Feline ASC trilineage differentiation
(A) ASC adipogenesis. Lipid droplets were stained with oil red O after 10 days
induction (40x). (B) Early stage osteogenesis. Alkaline phosphatase (ALP) was
stained by 5-Bromo-4-chloro-3-indolyl phosphate/ nitro blue tetrazolium chloride
after 10 days induction (10x). (C) Late stage osteogenesis. Extracellular matrix
calcium was stained by alizarin red after 20 days induction (5x). (D) Early stage
chondrogenesis. Cell pellet was stained with alcian blue after 20 days culture in
induction or stromal medium (E) (64x).
3.3.5 Multipotentiality
The CFU frequency indicates the percentage of cells within a population that are
capable of forming CFU-F, -Ad or -Ob colonies. Due to low expansion rates after P3,
P5 revitalized cells were not included in CFU assays. The SVF CFU-F frequency was
1.6% (Table 10). Fresh cells at P0 and 1 had significantly higher CFU-F, -Ad, and Ob frequencies than P3 and 5. Revitalized P1 cells had significantly higher CFU-F, Ad, and -Ob frequencies than P3. Also, fresh P3 cells had significantly higher CFU-F
and -Ob frequencies than revitalized cells.
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Table 10 Colony forming unit (CFU) frequencies (mean ± SEM) for fresh and
revitalized feline ASCs
CFU Frequencies (%, mean ± SEM)
Passage

Cell type

CFU-F (%)

CFU-Ad (%)

CFU-Ob (%)

SVF

Fresh

1.6

0

Fresh

2.2±0.2a

0.3±0.02a

0.7±0.2a

Fresh

2.0±0.7a

0.3±0.08a

0.6±0.04a

Revitalized

1.9±0.4a

0.3±0.03a

0.5±0.1a

Fresh

0.1±0.01*,b

0.03±0.01b

0.1±0.01*,b

Revitalized

0.04±0.01b

0.02±0.01b

0.03±0.03b

Fresh

0.02±0.005c

0.002±0.002c

0.01±0.01c

1

3

5

Values with asterisks are significantly different from revitalized cells within passage
and CFU. Values with different lower-case letters within passages are significantly
different.
3.3.6 Immunophenotypes
The majority of P0, 1, 3, and 5 cells were CD9+, CD29+, CD44+, CD90+, and CD105+,
and there were no differences between new and classic isolation methods (Figure 8).

New

Classic

CD9

CD29

CD44

CD90

CD105

Figure 8 Representative immunophenotyping of P0 feline ASCs isolated using the
new and classic methods
The black graphs represent stained cells and the green graphs autofluorescence.

	
  

46

	
  
Using the new method, P0 had significantly fewer CD105+ cells than P1, while P5
cells had significantly fewer CD9+ and CD105+ cells than P0 and 1 (See A in Figure
9). There were significantly more CD29+ cells at P1 and 3 than P5. Revitalized P3
cells had significantly more CD9+ and CD105+ cells than P1 (See B in Figure 9).
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Figure 9 Cell percentages (mean ± SEM) of P0, 1, 3, and 5 fresh (F) and revitalized
(R) ASCs positive for CD9, CD29, CD44, CD90, or CD105
Columns with different letters within markers are significantly different from each
other (P < 0.05).
3.3.7 Expression of marker genes
Compared to P3 cells, induced P1 cells had significantly higher mRNA levels of
peroxisome proliferator-activated receptor gamma (PPAR-γ) and leptin following
adipogenic induction for both fresh and revitalized populations (See A,B in Figure 10).
Both fresh and revitalized P1 cells following osteogenic induction also had
significantly higher mRNA levels of osteoprotegerin (OPG) and collagen 1α1
(Col1α1) (See C,D in Figure 10). Both fresh and revitalized P1 cells after adipogenic
or osteogenic induction had significantly higher levels of Sox2 than P3 (See E in
Figure 10). Revitalized adipogenic P1 cells had significantly higher levels of Nanog
than P3 (See Fin Figure 10). Also, fresh adipogenic P3 cells had significantly higher
Nanog levels than revitalized cells. Additionally, both fresh and revitalized P1 cells
had significantly higher Nanog levels than P3.
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Figure 10 Fold change (mean ± SEM, n=5) of adipogenic and osteogenic target gene
mRNA levels in feline ASCs
ASCs following adipogenic or osteogenic induction were compared to parallel
cultures maintained in stromal medium Columns with different letters within markers
are significantly different from each other (P < 0.05). Columns with asterisks are
significantly different from revitalized cells.
3.4 Discussion
Stromal cell therapies may be an option for numerous feline pathologies. An efficient
method to isolate ASC from feline epididymal adipose was developed in this study.
Consistent with the hypothesis, a therapeutic dose of ASC was available within three
cell passages (P2) of fresh or cryopreserved cells that retained their MSC properties.
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Decreasing cell expansion, multipotentiality and MSC immunophenotype with
increasing passages suggests that early passages of fresh or revitalized feline
epididymal ASCs from have the greatest potential for therapeutic benefit. Hence,
ASCs can be harvested from tissue that is routinely discarded and preserved for later
administration, obviating the need for additional surgery or potential risks of
allogenous cells. Further, the techniques to identify MSC surface marker expression
in this study benefit efforts to isolate homogenous ASC populations for
characterization and expansion.
There are several advantages to using epididymal adipose tissue for ASC
isolation. It is a deposit of pure WAT in contrast to subcutaneous adipose tissue, a
combination of BAT and WAT [207, 208]. White adipose tissue contains a higher
ASC density compared to BAT [207]. Further, most cats are castrated as young
animals. Numerous studies support the higher density and greater multipotentiality of
ASC harvested from young versus older donors [213-215]. Cell banking for later
administration is a feasible approach to address the consequences of aging in feline
companions. While the results of this study are currently limited to toms, it is logical
to extend this work to adipose tissue removed during routine spay procedures on
queens.
Despite promising early results from clinical application in a number of
species including cats (Table 11), standard protocols for ASC isolation, expansion and
clinical application are lacking. Cell isolates are by nature heterogeneous and contain
adipocyte precursors, mature endothelial cells, haematopoietic cell populations and
tissue-specific progenitor cells [111].

Further, isolation procedures are generally

customized for different adipose tissue harvest sites [216]. Significant variability
among isolates can translate to unpredictable post-implantation behaviour [217].
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Table 11 Therapeutic applications of MSCs
Trial

Species Source

Treatment
6

Chronic kidney
disease [151]

Feline

1 ~ 4 x 10
ASCs
105 BMSCs

Intrarenal

Chronic kidney
disease

Feline

1.47 x 106
ASC SVF/kg

Intrarenal

Type I diabetes
[218]

Canine

5 x 107
BMSCs

Intrahepatical

Lymphoma
[219-221]

Canine

Segmental bone
Canine
defects [158]
Meniscus
defects[48]

4 x 106
hematopoietic Intravenous
stem cells
125,000
BMSCs/cm2

Caprine 107 BMSCs

Normal levels of
serum thymidine
kinase and the
absence of peripheral
blood clonal T-cell
receptor gene
rearrangements
Enhanced bone
formation

Intraarticular

Enhanced tissue
formation and
reduced osteoarthritis

2 ~ 20 x 107
BMSCs

Epicardially

Type I diabetes
[217, 223-225]

Human

0.5 ~ 3 x 106
ASCs/kg

Intraportal or
intra-arterial

Type I diabetes
[226, 227]

Human

3 x 106
BMSCs/kg

Intravenously

Type II diabetes
Human
[228-230]

3 ~ 4 x 108
BMSC
SVF/kg

Retinal disease
[231]

107 BMSCs

	
  

2 of 4 cats with mild
increase in
glomerular filtration
rate and decrease in
serum creatinine
concentration
Creatinine improved
3.8%, BUN improved
19.6%
Average blood
glucose levels
significantly
increased

Ceramic carrier

Chronic
ischaemic
Swine
cardiomyopathy
[222]

Human

Results

Improved ventricular
function and reduced
size of infarct scar
Improvement of
biological marker and
no adverse effects
Induced prolonged
insulin independence

Improved metabolic
Intrapancreatical control and reduce
insulin requirements
No detectable
structural or
Intravitreally
functional toxicity
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Though inherent individual variability among animals cannot be avoided,
standardized isolation and characterization techniques for specific adipose deposits
may significantly enhance the predictability of ASC behaviour and efficacy following
administration.

The efficient, repeatable ASC isolation technique from feline

epididymal tissue established in this investigation is an option toward this goal.
Further, selection of ASC by surface marker expression may likely increase
consistency in in vitro and in vivo behaviour [99, 232].
The amount of adipose tissue available from excised castration tissue is about
a tenth of that typically harvested from other adipose depots [233]. Despite this, a
“dose” of cells was available within three cell passages in this study, using plastic
affinity to select for ASCs [234].

Inconsistent cell expansion can contribute to

differences among cell isolates since extensively expanded cells are technically “older”
than those that have been expanded as much [235]. While SVF colony numbers were
relatively low in this study, they were not significantly different among animals.
Further, cell seeding density was identical for all cell passages. Given the age at
which most of the cells will likely be isolated, they could be applied for congenital
conditions, chronic illness or later for age related problems. Thus, the expansion time
necessary for a characterized epididymal ASC isolate is unlikely to restrict use.
Kreb’s ringer buffer contains 4-5 fold fewer nutrients than DMEM. It was
used for collagenase digestion since DMEM components like high glucose and
sulfhydryl and chelator-containing amino acids inhibit collagenase activity [236-239].
Mechanical agitation and lengthened digestion times were applied to promote tissue
dissociation and facilitate collagenase activity, both of which can decrease cell
viability [240, 241]. Study findings including cell phenotype, morphology, CD and
DT and CFU frequencies were similar to those reported for cats and other species,
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confirming that the vigorous digestion did not inhibit subsequent cell function [25,
151, 172, 174, 193, 210, 234, 242].

The significant increase in CD105+ cell

percentages from P0 to P1 is consistent with ASC selection by plastic adherence [243,
244]. Decreased CD9+ and CD105+ cell percentages in late cell passages parallel the
observed reductions in multipotentiality based on CFU-Ad and -Ob frequencies and
tissue specific mRNA levels.
Differentiation media used in this study were optimized for feline ASC based
on existing knowledge from other species [25, 151, 174]. Adipogenesis induction
medium contained ETYA and indomethacin which promote lipid droplet formation
by PPAR-γ activation, and rabbit serum, a component of canine and equine ASC
adipogenic medium [25, 163, 181, 226].

Beta-glycerophosphate was added to

osteogenic medium after 10 days of culture to avoid colony delamination [245]. For
chondrogenesis, bone morphogenetic protein-6 was added to enhance proteoglycan
synthesis as reported for equine MSC [163, 246, 247]. The induction media used in
this study may be valuable for future feline ASC studies, especially in the area of in
vitro tissue generation.
Results from the present study demonstrate that tissue excised from routine
castration is a reliable source of feline ASCs. The New method of adipose tissue
digestion results in a therapeutic dose of functional ASCs for potential autologous
administration. Cell cryopreservation is a mechanism to maintain potent ASCs for
later application that will reduce cell expansion time and avoid tissue harvest from
sick or injured patients. Use of MSC surface antigens and major histocompatibility
markers to isolate homogenous ASC populations is a natural extension of the work
reported here that may enhance cell efficacy and reduce the potential for rejection or
antigenic stimulation [53].

	
  

Prior to implementation of ASC administration as a
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standard of care, standardized isolation and administration protocols as well as safety
and efficacy, should be established with preclinical investigations and randomized,
controlled clinical trials in accordance with established guidelines.
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CHAPTER 4. IN VITRO CANINE CRANIAL CRUCIATE LIGAMENT
REGENERATION USING ADULT INFRAPATELLAR ADIPOSE-DERIVED
MULTIPOTENT STROMAL CELLS, COLLAGEN SCAFFOLD AND PDS
SUTURES
4.1 Introduction
4.1.1 Cranial Cruciate Ligament Disease (CrCL)
The CrCL connects the lateral condyle of the femur and the anterior intercondylar
area of the tibia. Rupture of the CrCL is one of the most common causes of hindlimb
lameness in dogs. Sometimes, acute CrCL injury can occur due to trauma, when the
dog jumps, slips, make a sudden turn or steps into a hole and the relative forces
stressing the ligament exceed its breaking strength. However, only 20% of canine
CrCL deficiencies are due to trauma. The majority of CrCLs rupture due to
progressive and irreversible degeneration within the ligament itself [248, 249]. These
non-traumatic ruptures are called spontaneous CrCL rupture.

Both partial and

complete CrCL rupture accelerates development of osteoarthritis (OA), a highly
prevalent and progressive degenerative joint disorder which leads to pain, stiffness
and decreased range of movement in both animals and humans.

Age, genetic,

conformational, environmental, immune-mediated, and inflammatory factors can
contribute to development of OA [250-252].
Genetics exert a direct impact on the structural properties of the CrCL.
Labrador Retrievers, Rottweilers, and Newfoundlands have a higher risk for nontraumatic CrCL deficiency, while Greyhounds have a relatively lower predisposition
[253, 254]. A survey from 574 Newfoundlands showed 22% prevalence of CrCL
deficiency and 51% penetrance in the recessive mode of inheritance [255].

A

subsequent showed that four microsatellite markers from 4 respective chromosomes
associated with CrCL disease were found in a subset of 90 Newfoundlands.
Nonetheless, only 27% of CrCL deficient dogs were the result of genetic influence.
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Another report showed no significant differences between the gene expression
profiles of dogs with high risk of CrCL rupture and dogs relatively resistant to the
rupture [256]. But protease and extracellular matrix genes (aggrecan, caspase 8,
collagen 1A2, collagen 3A1, collagen 5A1, cathepsin B, cathepsin D, insulin-like
growth factor 1, lumican, MMP-2, MMP-9, cyclooxygenase 2, tissue inhibitor of
metalloprotease 1, and tenascin C) had higher expression in ruptured CrCLs
compared to intact CrCLs, suggesting involvement in ligament rupture.
Conformational factors include both pelvic limb and stifle abnormalities.
Genu varum (bow leggedness) is one of the most common conditions associated with
CrCL degeneration [254]. It often appears as a poor coxofemoral conformation
(dysplasia), femoral angulation, tibia internal rotation, proximal angulation and
medial patellar luxation [251, 257]. Narrowed intercondylar notch (ICN) in dogs
leads to impingement from the medial aspect of the lateral femoral condyle, or at the
level of the intercondylar roof of the fossa [258]. Another theory is based on a
biomechanical model developed by Slocum surrounding the tibial plateau angle [259].
Ground reaction forces propagate along the tibia while a shear force is generated by
the compression of the femur against a caudally oriented tibial plateau slope. This
theory is also the principle for the tibial plateau leveling osteotomy (TPLO). Patellar
tendons also contribute to joint reaction forces [260]. The patellar tendon determines
the alignment of the force generated by quadriceps contraction [261]. The TPLO is a
fairly complex procedure with some potentially unrecognized pitfalls where
iatrogenic errors can result in a change in limb angulation and rotation [262]
In CrCL disease, both humoral and cell-mediated immune responses are
recognized. The structure is covered by a synovial membrane and hence protected
from immune detection. However, once exposed, the CrCL can release antigens into
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the synovial fluid (SF) that stimulate autoantigenicity [263-265].

Also, COLI

released by injured CrCL was absorbed by macrophages, which became activated and
presented collagen as the antigen to native T cells and B cells for antibody production.
These antibodies were further released into synovial fluid, generating immune
complexes. Or the collagen was phagocytositized by macrophages which began
CrCL proteolytic degradation [266]. Need concluding statement
A number of biochemical factors have been discovered to induce the joint
inflammation, both pro-inflammatory and anti-inflammatory.

Different cytokines

affect the inflammation process at different stages of the immune response. The
imbalance between the pro-inflammatory and anti-inflammatory factors after CrCL
injury may cause OA occurrence, and induce the upregulation of immunoregulatory
factors, such as cytokine inhibitors and growth factors [267]. Cytokines such as IL1β, IL-1rα, IL-6, IL-8, IL-10 and TNF-α are reported to be involved in CrCL injury
[268-270]. It has also been confirmed that SF in joints with ruptured CrCLs contains
collagen [271], glycosaminoglycan [272], proteoglycan, and fibronectin [273]. These
particles may initiate and promote OA.
4.1.2 CrCL Pathogenesis
Ligament pathogenesis is a complicated series of events, including changes in
ligament cells and extracellular matrix at molecular, biochemical, microstructural and
macrostructural levels [274]. They share many degradative molecules with the
initiation and progression of OA. Matrix metalloproteinases (MMP) are reported to
be involved in both ligament pathogenesis and initiation of OA in CrCL disease, as
well as collagenases [275], gelatinases [276], cathepsins [277]and other degradative
enzymes. Recently, MMP expression in stifles with normal and partially disrupted
canine CrCLs was compared [278]. The intact ligaments produced substantially more
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MMP-2 and MMP-3 in response to explant ligament media in vitro compared to
partially disrupted ligaments after 6 days of culture.

This study confirmed the

capacity of intact CrCLs to secret degradative enzymes when exposed to an abnormal
environment. Because MMP-3 is able to cleave and activate other MMPs, it is
possible that MMP-3 plays an essential role in both CrCL pathogenesis and initiation
of OA. Interestingly, additional research showed that MMP-3 levels in synovial fluid
were increased in older hounds compared to younger beagles with normal CrCLs
[277]. Therefore, the level of MMP-3 expression can be used as a target to detect the
occurence and condition of CrCL disease.
4.1.3 Cranial Cruciate Ligament Repair
Tissue repair requires coordination of a series of cellular and molecular events.
Initially, local or undifferentiated cells start tissue repair by migrating into the injured
area and proliferating [279].

Concurrently, physiological angiogenesis provides

sufficient nutrients and oxygen to support cell survival.

Cells going through

proliferation and differentiation produce new extracellular matrix (ECM) and to
restore the structure and the function of the damaged area [280]. The challenge of
tissue repair is creating a well-organized ECM to direct progenitor cells while
maintaining tissue structure and strength [281].
Generally, cells in ligaments are renewed at a relatively slower rate than most
soft tissues, so ligaments heal more slowly than other tissues [282]. For extraarticular ligaments like the medial collateral ligament (MCL), spontaneous healing
occurs in 4 phases. Phase I occurs within the first 72 hours with bleeding and
hemostasis. The hematoma helps to bridge the torn ends. Then, in phase II,
inflammatory cells, including monocytes, leukocytes, and macrophages aggregate,
while fibroblasts slowly induce granulation tissue formation, and synthesize type III

	
  

57

	
  
collagen, and type I collagen to a lesser extent. Cells proliferate and matrix deposition
forms a vascular neo-ligament in phase III, followed by the organization of
collagenous tissue arrangement and synthesis of higher proportion of type I collagen
and long-term remodeling in phase IV [283].
In the case of CrCL repair, when the thin synovial sheath of the CrCL is
ruptured, blood dissipates into the synovial fluid, making it difficult to form a
localized hematoma with cytokines, growth factors, and reparative cells at the injury
site [284, 285]. Also, because the torn components retract, there is a high residual
strain in the intact CrCL [286]. Additionally, compared with cells derived from other
ligaments, CrCL fibroblasts have lower mobility, proliferation and metabolic
activities, and matrix production tendencies, poorer adhesive strength, and higher
MMP expression [287-291]. The CrCL therefore has limited healing capabilities
compared to other ligaments.
A wide range of growth factors and cytokines have been reported to directly
interact with transmembrane receptors to regulate cell functions during tissue repair
[292]. Mechanisms are, in general, only partially described. Platelet-derived growth
factor (PDGF) acts as a mitogen to help connective tissue cells grow, change shape
and motility and reorganize actin filaments. Transforming growth factor-beta (TGF-β)
is strongly related to morphogenicity and collagen synthesis. Type I insulin-like
growth factor (IGF-I) is fully involved in cell survival, growth and metabolism.
Finally, vascular endothelial growth factor (VEGF) and hepatocyte growth factor
induce endothelial cell proliferation and migration, and angiogenesis [293-296].
Multiple growth factors were found to contribute to CrCL repair. Myostatin,
also referred to as growth and differentiation factor 8 (GDF-8), is a member of the
TGF-β1 superfamily of GDFs that is highly expressed in skeletal muscle [297, 298].
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First, myostatin and its receptor, the type IIB activin receptor (ActRIIB), were found
to increase cell proliferation and the expression of type I collagen in primary
fibroblasts in the leg tendons of mice [298]. Myostatin binds theActRIIB and type I
co-receptor (Alk4/5) to regulate the expression of downstream target genes such as
myogenic differentiation protein (MyoD) and myogenic factor-5 (Myf-5) via a TGF-β
signaling pathway [299]. With myostatin treatment, mouse tendon cells increase
fibroblast proliferation and type I collagen expression [300].

Similarly, with

myostatin treatment, proliferation, extracellular matrix synthesis and the expression of
tenascin C (TNC), type 1 collagen and transforming growth factor-β1 increases in
CrCLs of myostatin-deficient mice. Additionally, compared to injured MCLs, there
was limited expression of PDGF and TGF-β1 in injured CrCLs in rabbit CrCL and
MCL injury models [301]. Lower expression in the CrCLs was attributed to reduced
vascular supply. The PDGF was localized intracellularly in tenocytes and
epitenocytes, reaching maximum levels 4 days after injury. TGF-β1 was found in
ECM on post-injury days one and two, and decreased with time, but intracellular
expression was increased in epitenocytes throughout the tendon and endotenocytes at
the injury site and reached the maximum on post-injury day seven. bFGF mainly
expressed in ECM of the tendon, but rarely in tenocytes, and reached the maximum
on day 28 after injury. These growth factors may be used for further analysis to study
CrCL injury and repair.
4.1.4 Cranial Cruciate Ligament Regeneration
Traditional ACL repairs use biological based grafts that have good initial mechanical
strength and promote cell and tissue growth. However, they have a number of
disadvantages. Autografts from patellar hamstring or quadricep tendons are limited,
and may cause donor site morbidity, increased recovery time and pain [121]. The
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material strength of allografts and xenografts is compromised during harvest and
processing [127, 128]. Concerns also include disease transmission, infection and
immune rejection [123, 124]. Tissue engineering provides a promising alternative to
auto- and allografts.
Adult MSCs do not express MHC II proteins, so they have immune privilege
and can be transplanted into allogeneic hosts [302]. Also, they grow faster and
secrete more COLI than ligament fibroblasts, and rabbit iliac crest BMSCs are
reported to be a superior choice for CrCL regeneration compared to fibroblasts from
the CrCL and MCL [118]. Those cells were detectable for at least 6 weeks after
implantation. Additionally, orthotopic MSCs have greater commitment to tissuespecific lineages than those from heterotopic sources [167]. Intra-articular stromal
cells showed better expansion capacity and potential for joint tissue regeneration than
cells from other sources [177]. Species, cell passage and cryopreservation effects are
also considerations for cell selection. In our previous study, canine infrapatellar (IFP)
adipose-derived stromal cells (ASCs) up to P3 had higher proliferation rates,
differentiation potential, MSC surface marker expression and lineage-specific gene
expression than other intra-articular MSC sources.
As a required component in tissue regeneration engineering, a biological
scaffold that is tailored to stem cells is central to their application for CrCL
regeneration. Scaffolds can be designed to stimulate and direct tissue formation in
order to replace parts or whole tissue structures. Scaffolds with appropriate pore size
and microporosity (high interconnectivity between pores) can improve scaffold cell
attachment, viability and tissue ingrowth [303]. The ideal pore diameter is around
200 µm for soft tissue [124].
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Scaffold material selection is important for biocompatible scaffolds. The ideal
replacement should possess similar physical and mechanical properties, degradability
and structural integrity as the original tissue. For human ACL, the scaffold should
withstand up to 3% physiologic strains during normal knee motion [304].
Additionally, the material needs to resist degradation by intra-articular inflammatory
metabolites and proteolytic enzymes, such as plasmin [305], MMP [306] and
glycosides [307].
Synthetic polymers are used for biocompatible scaffolds.

Many are

biodegradable materials like poly glycolic acid (PGA), poly lactic acid (PLA), or their
copolymers, polyurethane urea (PUU), poly desaminotyrosyl-tyrosine ethyl carbonate
(poly (DTE carbonate)), polydioxanone (PDS) and poly caprolactone (PCL) [308,
309]. The mechanical properties can be controlled by altering polymer concentrations,
molecular weighst, crystallinity, structure and ratios. For example, braided PLLA
scaffold provides specific pore size, well-integrated pores, resistance to wear and
rupture, and mechanical properties comparable to the human ACL [310]. Also, the
dense connective tissue infiltrates and bonds to the braided filaments 12 weeks afater
implantation in adult New Zealand white rabbits [311, 312].
Since the major component of the ACL is type I collagen (COLI), it is popular
in ACL tissue engineering studies [313, 314]. Type I Collagen is FDA-approved and
biocompatible, and it can be formulated as a flexible gel, sponge or fiber [315]. It
supports MSC attachment, proliferation and migration [316]. However, it has low
biomechanical strength and relatively high degradation rates, and the use of COLI
alone was found ineffective in improving CrCL healing in minipigs [317, 318]. This
indicates that COLI should be combined with other materials with stronger
mechanical properties.
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Silk is another non-cytotoxic natural polymer with good biocompatibility,
relatively slow degradability and excellent mechanical properties [319]. It can be
used to create a structure similar to the ACL, and both human MSCs and fibroblasts
attach, proliferate and form ECM on silk scaffolds [320, 321]. Composite scaffolds
of nanofibrous PLGA and silk coated with bFGF support rabbit MSC attachment,
proliferation and ligamentocyte differentiation [322, 323].
Different reagents have been applied to promote CrCL healing and formation.
Some factors included in growth medium include TGF and epidermal growth factor
(EGF), TGF and insulin (applied sequentially), insulin-like growth factor (IGF-I),
bFGF, VEGF, platelet-derived growth factor (PDGF), and growth and differentiation
factor (GDF). Platelets are activated COLI and secrete growth factors such as PDGF,
TGF-b and VEGF[324].

Cytokine mixtures have been shown to improve cell

proliferation but also suppress inflammation in humans [325]. A combination of
primary suture repair and plate-concentrate resulted in greater stiffness, load at yield,
and maximum tensile load after 4 weeks, and improved mechanical properties were
observed as far as 14 weeks in a porcine model of CrCL wound repair [326, 327].
Previously, we identified the IFP to be the optimal MSC source for canine
intra-articular tissue engineering [233]. These MSCs maintain their potency after
cryopreservation up to passage (P) 3 [328]. Use of MSCs from healthy donors may
have advantages of generating neo-tissue as well as immunoregulatory effects, since
the number and differentiation potential of MSCs influences by disease and age [51,
104, 167]. The objective of this study is to generate viable canine neoligament tissues
from adult canine IFP ASCs on COLI CrCL templates under dynamic perfusion
bioreactor culture conditions in vitro. We hypothesized that canine IFP ASC
attachment, proliferation, ligament differentiation and collagen deposition on COLI
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CrCL templates will be higher with ligamentogenesis medium compared to stromal
medium under identical perfusion bioreactor culture conditions.
4.2 Material and Methods
4.2.1 Study Design
Tissue harvest procedures were approved by the Institutional Animal Care and Use
Committee (protocol #10-004). The ASCs from 6 mixed breed female dogs were
isolated from IFP immediately after tissue harvest. Cryopreserved cell passage (P0)
ASCs were revitalized and expanded to P3. Canine CrCL templates were constructed
from #2 PDS II and bovine corium COLI (AviteneTM UltrafoamTM Collagen Sponge,
Davol Inc., subsidiary of C.R. Bard, Inc. Warwick, RI, USA). Cells (6 x 106
cells/scaffold) were seeded onto the templates using custom perfusion bioreactor
chambers. Constructs were cultured in stromal or ligament-specific induction
medium up to 21 days with dynamic perfusion in the same chambers (2
constructs/cell isolate/medium, 24 total). Loading efficiency was evaluated 2 hours
after cell seeding (n=3). Samples (6 mm diameter) were collected 1 (upper), 2
(middle) and 3 (lower) cm from the top of the template using a biopsy punch
immediately after loading and 7, 14 and 21 days of culture (Table 1). Samples were
evaluated for cell proliferation (alamar blue), viability (calcein-ethidium bromide
viability stain) and collagen deposition (sirus red stain). Procollagen was quantified
in the medium (enzyme linked immunosorbant assay), and extracellular matrix (ECM)
and cell ultra-structure was observed (scanning electron microscopy) at the same time
points. Ligamentogenesis target gene expression (quantitative real-time PCR) was
evaluated in ligament tissue at each time point as well.
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Table 12 Sample Collection and Outcome Assessments
Collection
Time Points
(Days of
Culture

# of Cell
Isolates

Samples
/ Cell
Isolate

5

2

3

1

Random

1

1

0.06cm3

Random

1

1

7, 14, 21

0.06cm3

Random

6

2

ELISA

7, 14, 21

200ul

Culture
Medium

4

2

Quantitative
real-time PCR
(qRT-PCR)

7, 14, 21

1.2 cm3

Upper half or
lower half

4

1

Sample
size

Outcome

Assay

Cell
Proliferation

Alamar Blue
(AB)

7, 14, 21

0.06cm3

Cell Viability

CLSM

7, 14, 21

0.06cm3

7, 14, 21

0.06cm3

7, 14, 21

Sirus Red (SR)

Ultrastructure
Microstructure
Collagen
Deposition
Procollagen
Synthesis
Ligamentogen
esis Gene
Expression

Scannine
Electron
Microscopy
(SEM)
Light
Microscopy
(LM)

Location of
samples
1, 2 and 3 cm
from the top
of the
template
1, 2 and 3 cm
away from
the top of the
template

4.2.2 Cell Harvest, Expansion and Preservation
The IFP adipose tissue was collected aseptically from normal stifles of six mixed
breed female dogs (23.1 ± 0.9 kg, 3.3 ± 0.4 years, mean ± SEM). Adipose tissue was
minced and digested at 37°C in an equal volume of Dulbecco's Modified Eagle
Medium (DMEM) with 1% bovine serum albumin (BSA) and 0.1% type I collagenase
(Worthington Biochemical, Lakewood, NJ). After washing with 1% BSA and
centrifuging (260 g, 5 min), the resulting stromal vascular fraction (SVF) pellet was
seeded at 5 x 103 cells/cm2 in stromal medium (DMEM-Ham’s F12, 10% fetal bovine
serum (FBS), 1% antibiotic/antimycotic solution) followed by culture under standard
conditions (37°C, 5% CO2). For purposes of this study, the initial cell isolate is
considered the stromal vascular fraction and the first cell passage is considered P0.
Cell seeding density was 5 x 103 cells/cm2 and cell passages were performed at 80%
confluence. Passage 0 cells were detached with 0.25% trypsin, and cell aliquots (1 x
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106 cells/ml) in cryopreservation medium (80% fetal bovine serum (FBS), 10%
DMEM, 10% dimethylsulfoxide) were maintained in liquid nitrogen for a minimum
of 30 days.
4.2.3 Immunophenotype – flow cytometry
Following thawing (37°C, 1 min), P0 cells were cultured in stromal medium and
expanded to P3. Cell aliquots (P3, 5x103 cells/dog, n=6) were combined in 200 ml
PBS and incubated with 5 µg of unlabeled CD29 (α-human, catalog #610468, BD
Biosciences, San Jose, CA, USA), PE-CD34 (α-dog, catalog #559369, BD
Biosciences), FITC-CD44 (α-dog, catalogue # 115440, eBiosciences, San Diego, CA,
USA), FITC-CD45 (α-dog, catalog #125451, eBiosciences) or CD90-PE (α-dog,
catalog #125900, eBioscience,) antibodies for 30 min at room temperature. For CD29,
cells were washed with phosphate buffered saline (PBS). Indirect
immunofluorescence was performed by incubation with goat Ig-FITC (α-mouse,
catalogue #F9006, Sigma Aldrich, Saint Louis, MI, USA) for 30 min at room
temperature. Following incubation, cells were washed with PBS and fixed with 2%
paraformaldehyde. Surface antigen expression was determined based on comparisons
with negative controls illustrated on 10,000 even histogram plots using a
fluorescence-activated cell sorting flow cytometer (FACSCalibur, BD Biosciences)
and software (CellQuest Pro, BD Biosciences).
4.2.4 Perfusion bioreactor system
Following revitalization and culture expansion as described above, P3 cells were
detached with trypsin, rinsed with PBS, and resuspended in stromal medium. Cells
suspended in stromal medium were loaded onto templates with a perfusion bioreactor
system (Figure 11). Each system was composed of two custom-made bioreactors
connected to a 10 ml disposable vessel used as the medium reservoir
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(Synthecon,Houston, TX) on their lowermost ends and to a peristaltic pump (Ismatec
404b, Glattbrugg, Switzerland) on their uppermost ends with 4.8 mm inner diameter
flexible tubing (Tygon, Compagnie de Saint-Gobain, Courbevoie, France). The
vessel provided oxygenation via a flat, silicone rubber gas transfer membrane. The
bioreactors were made of polyvinyl chloride. One bioreactor in each system had a
three-way stopcock at its lowermost end and a 0.22 µm syringe filter (Millipore,
Billerica, MA, USA) between tubing attached to the bioreactor and tubing attached to
the pump. Both bioreactors were 50 mm in length and had a 20 mm inner diameter
(See A-C in Figure 12). Both ends were made with female screw locks. Within each
chamber was a 45 mm long structure composed of two circular ends connected by 5
mm wide pieces (See D in Figure 12). Across the midpoint of each circular end, a 15
mm piece extended. The pieces on each end were offset 90 degrees to each other.
The ends of the template were tied to the bisecting pieces such that the figure 8
configuration of the scaffold was maintained and the ends of the template were offset
by about 45 degrees to replicate the CrCL structure. Each template was pre-soaked in
70% ethanol for 30 sec, UV sterilized for 15 min, hydrated with 10 µg/ml fibronectin
in PBS for 30 minutes, and then tied to the frame as described above. The frame was
inserted into the chamber and the ends of the chambers were sealed by parafilm.
4.2.3 PLLA: PEG scaffold construction and cell loading
A native canine CrCL was fixed in 1% PFA for 7 days and scanned with
NextEngine® Desktop 3D Scanner and ScanStudioTM software (NextEngine, Santa
Monica, CA). The 3D prototype was printed using acrylonitrile butadiene styrene
(ABS) and casted into a polydimethyl siloxane (PDMS) mold. The scan was modified
with two cylinders (0.2 mm in length) on each end using Rhino® (McNeel North,
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Figure 11 Perfusion bioreactor system
The original perfusion system was modified with two custom-made chambers (Part I)
and medium reservoir with gas exchange export (Part II) (C). The system was
connected to a peristaltic pump (Part III) and an external computer (Part IV). The
flow direction and rate were controlled by Labview program.
America, Seattle, WA) and autoCAD were made by SolidWorks® (SolidWorks
Waltham, WA). The PLLA (7%, wt) were dissolved in 1,4-dioxane, heated at 60°C,
stirred for 2.5 hrs, cooled to RT, mixed with PEG (7%, wt) in a ratio of 6:4, and
injected into the mold. The scaffold was unidirectionally freeze dried at -88°C at a
rate of 1.6 ml/hr for 48 hrs, and divided into 6 parts with similar sizes [329].
All parts were gas sterilized with ethylene oxide before being assembled. The
system was first loaded with medium through the stopcocks towards the chambers at
both sides, and then followed by ASC suspensions (3 x 106 cells/scaffold) using the
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original perfusion bioreactor at a fluid flow rate of 1 ml/min for 2 hrs in an incubator.
Flow direction was reversed after medium reached the filter so that scaffolds
remained immersed during the loading process. Scaffolds without cells were treated
identically.

Figure 12 Custom-designed chamber
The chamber was 50 mm in length and had a 20 mm inner diameter and was adapted
to the system with luer locks and a stopcock (A, C). The inner apparatus that could be
inserted into the chamber was used to hold the scaffold with a 45 degree twist of both
ends (B,D).
After loading, constructs were transferred into a 6 well plate and cultured in 4
types of media (10% PRP, 1% PRP, 0.1% PRP and stromal control) for up to 21 days.
Scaffolds without cells were cultured as a negative control. The leftover media in the
bioreactor was collected and tubings were trypsinized. Cell loading efficiency was
calculated as (initial cell number – cells in the medium)/ initial cell number x 100%.
4.2.3 Template construction and 3D culture
The CrCL template frame was constructed using a 70 cm section of #2 PDS II in 4, 2
cm long figure-8 shapes (See A in Figure 13). The center of the figure-8 was secured
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with two loops of suture wrapped around the structure and tied with a square knot. A
5 x 4 x 0.3 cm sheet of COLI moistened slightly with PBS was wrapped around the
frame, overlapping about 3 mm. COLI The sponge was then saturated with medium
causing it to shrink 30% and fit tightly to the frame. The COL sheet was secured to
the PDS frame with a Chinese finger trap of #2-0 Vicryl (See B in Figure 13). Each
template was pre-soaked in 70% ethanol for 30 sec, UV sterilized for 15 min,
hydrated with 10 µg/ml fibronectin in PBS for 30 minutes, and then tied to the frame
as described above. The frame was inserted into the chamber and the ends of the
chambers were sealed by parafilm.

Figure 13 Template construction
The PDS*II #2-0 was used to configure the shape of major bands of the CrCL (A).
The template was wrapped by collagen I scaffold and wrapped within a Chinese
finger trap of #2-0 Vicryl (B). The template was secured in the inner apparatus (C).
Fluid flow direction and rate were controlled by LabVIEW (v8.5, National
Instruments Corporation, Austin, TX, USA).

Systems were primed with 48 ml

ligament induction medium or stromal medium through the lowermost stopcock
followed by addition of MSC suspensions (1 ml, 6 x 106 cells/template, 2.5 x 106
cells/cm3) through the stopcock on the top of each bioreactor.

Perfusion was

performed (37ºC, 5% CO2) at a fluid flow rate of 1 ml/min up to 21 days. Flow
direction was reversed after medium reached the top of a bioreactor so that scaffolds
remained immersed. The medium was refreshed every 7 days through the medium
reservoir.
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4.2.4 Cell viability and toxicity
For zinc medium, 3 replicates of 1.28 x 104, 6.4 x 103, 3.2 x 103, 1.6 x 103, 8 x 102, 4
x 102, 2 x 102, or 50 cells/well were incubated in a 96-well plate overnight in 4 types
of zinc medium (0, 5, 10 or 20 µM ZnCl2).

The toxicity of the medium was

determined using alamarBlue reagent (Invitrogen, Carlsbad, CA). Cells were rinsed
with PBS, and incubated with 10% alamarBlue™ for 4 hrs. The fluorescence was
measured using an excitation wavelength of 530 nm and an emission wavelength of
590 nm using a fluorescence microplate reader (Biotek, Winooski, VT).
The viability of cells on COLI scaffold was also evaluated using alamarBlue™.
Samples immediately and 7 days after loading from both Zinc and stromal control
groups were collected using a biopsy punch (6mm) from the top, medium and bottom
area of the construct in duplicates. Samples were further incubated with 10%
alamarBlue for 4 hrs, aliquots (100 µL) were placed in a 96-well plate, and
fluorescence was measured. For growth factor medium, samples were similarly
collected from four time points, immediately after loading, 7, 14 and 21 days of
culture. Cell numbers were determined on a standard curve generated from known
cell numbers.
4.2.5 Cell Viability – Confocal Laser Scanning Microscopy
Samples were rinsed with PBS and incubated in darkness for 30 min at room
temperature with 5 µM calcein and 2 µM ethidium bromide (EB) (Sigma Chemical
Co., St. Louis, MO) in 200 µL PBS such that live cells fluoresced green while nonviable cells fluoresced red. A total of 20 consecutive photomicrographs (20x) of the
entire sample cross-section along the thinnest side (2 mm) were generated every 100
µm using a spectral confocal laser scanning microscope digital imaging system (Leica
TCS SP2, Leica Microsystems, Buffalo Grove, IL, USA).
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4.2.6 Ultra Structure – Scanning Electron Microscopy
Samples were fixed (2% PFA and 1.25% glutaraldehyde in 0.1 M sodium cacodylate
(CAC) buffer, pH 7.4) for 1hr at room temperature and transferred to buffer (3%
glutaraldehyde in 0.1 M CAC buffer, pH 7.4) for 30 min. Samples were rinsed with
washing buffer (5% sucrose, 0.1 M CAC buffer, pH 7.4), post-fixative buffer (1%
osmium tetroxide in 0.1 M CAC buffer, pH 7.4) and water, serially dehydrated,
critical point dried, and sputter coated with gold. They were observed with a
scanning electron microscope at 15 kVP (Quanta 200, FEI Company, Hillsboro, OR).
4.2.7 Collagen deposition – Sirius Red
Constructs were digested with 500 µl of pepsin solution (0.25 mg/ml), and stained
with Sirius red collagen detection kit (Chondrex, Redmond, WA) according to the
manufacturer’s instructions. Absorbance was read at 540 nm using a microplate
reader (Biotek, Winooski, VT). Values were normalized to scaffold only. The
collagen in each sample was extrapolated from a standard curve provided with the kit.
4.2.8 Procollagen Synthesis – Procollagen I N-terminal Peptide (PINP) Enzyme
Linked Immunosorbant Assay (ELISA)
Concentration of procollagen I N-terminal peptide (PINP) was measured in medium
when medium was changed every 7 days. Media were collected from each chamber
and the reservoir. Samples were stored at -80°C, thawed on ice and thoroughly mixed
before using. PINP levels were measured using the canine PINP ELISA kit (Biotang,
Framingham, MA) according to manufacturer’s instructions.
wavelength of 450 nm was measured.

Absorbance at a

Concentrations were determined from a

standard curve provided with the kit. Concentrations in the results reflected the PINP
release in the time period since the prior media changed.
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4.2.9 Target Gene Expression - qRT-PCR (quantitative reverse transcriptionpolymerase chain reaction) mRNA levels
Constructs were rinsed with PBS, and homogenized (TissueLyser II, Qiagen,
Valencia, California, USA) in TRIzol reagent (Sigma). Total RNA was extracted by
phenol-chloroform extraction according to TRIzol reagent’s instructions. Quantity
was determined with a ND-100 spectrophotometer (NanoDrop Technologies,
Wilmington, DE), and only samples with an A260/A280 ratio higher than 1.7 were
used.

mRNA was reverse transcribed into cDNA using a QuantiTect Reverse

Transcription Kit (Qiagen, Hilden, Germany).

Canine-specific primers against

collagen I (col1), collagen III (col3), biglycan (BGN), decorin (DCN), tenascin-c
(TCN), fibronectin (FN) and tenomodulin (TNMD) were designed using Primer3 and
annotation databases available at the University of California, Santa Cruz (UCSC)
Genome Browser database (http://genome.ucsc.edu/) (Table 14).

qRT-PCR was

performed in duplicate using a QuantiTect SYBR Green PCR Kit (Qiagen) in a 384
well PCR plate. PCR amplification was performed using Applied BioSystems 7900
Real-Time PCR System (SDS v2.4; Applied Biosystems, Carlsbad, CA). In the
present study, the data was normalized to GAPDH, and presented as the fold change
in target gene expression relative to the stromal control according to 2-ΔΔCt [176].
4.2.10 Statistical analysis
Values are presented as mean ± SEM. Two-way ANOVA models were applied to
determine effects of culture time and induction medium on cell metabolic activities,
collagen deposition and procollagen synthesis with Tukey’s post-hoc tests. One-way
ANOVA was used to analyze mRNA expression levels. Significance was considered
at P<0.05.

	
  

72

	
  
Table 13 Canine-specific primer sequences for ligament differentiation
Forward Primer

Reverse Primer

GAPDH TGGCAAAGTGGATATTGTCG

AGATGGACTTCCCGTTGATG

Col1

CTATGACCGAGACGTATGGA

GTTTCTTGGTCGGTAGGTGAC

Col3

CAGAGATCCCATTTGGAG

CATTTCTCCCAGGAATACC

BGN

CCACAACCAGATCCGCATGAT AGAAGTCGTTGACGCCCAC

DCN

CTCTAGCCAACACTCCTCAT

GGCAGAAGTCATTAGATCCG

TNC

CCACAATGGCAGATCCTTC

CCTTCCAGTGGAACCAGTTA

FN

GGTTTGTACCTGTTACGGAG

CAGATCATGGAGTCCTTAGG

TNMD

CCAGCAGAAAAGCCTATTG

GACCACCCACTGCTCGTTT

4.3 Results
4.3.1 PLLA: PEG scaffold construction
A CrCL structure mold was successfully printed (Figure 14A). However, during
polymer injection, the mold split and polymers leaked during freezing.

Further

modifications were made with two columns by both sides, one for injecting materials
and the other for air ventilation (See B-D in Figure 14). The outside structure of
PLLA: PEG scaffold was similar to the native CrCL, and the inside pores were 44 x
22 µm2 (See A, B in Figure 14).
4.3.2 Loading Efficiency
The loading efficiency for the PLLA: PEG scaffold in stromal medium was 83%
(Figure 15). With fibronection coating, collagen scaffold had significantly higher
loading efficiency than non-coated groups. No significant changes were shown using
different loading medium with PLLA: PEG or collagen scaffold.
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Figure 14 PLLA: PEG scaffold
The 3D prototype was printed using acrylonitrile butadiene styrene (ABS) (A), and
modified with columns (B,D). Rhinoceros 4.0 prototype C (C).
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Figure 15 Loading efficiency (mean ± SEM, n=3)
PLLA: PEG and collagen scaffolds were loaded in stromal medium or ligament
induction medium for 2 hrs with or without coating with fibronection (Fn). Needs
more description. What is shown here?
4.3.3 SEM Images of PLLA: PEG Scaffold Cultured in PRP and stromal media
The construct cultured with 10% PRP was fully covered with platelets after 21 days of
culture (See C in Figure 16). Cells were also evident in scaffolds cultured in other
media, 1% PRP (See D in Figure 16), 0.1% PRP (See E in Figure 16) and stromal
medium (See F in Figure 16). However, the scaffold failed to maintain the structure
during 3D culture. Different types of scaffold were used in later studies.
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Figure 16 Scanning electron photomicrograph of PLLA: PEG scaffold
The outside was similar to native CrCL (A), and the inside was porous (B). The
scaffold was covered with platelets (red arrows) following culture in 10% PRP
medium (C). The IFP ASCs (red arrows) were attached to the surface of the scaffold
in 1% PRP medium (D), 0.1% PRP medium (E) and stromal medium (F).
4.3.4 Cytotoxicity of ZnCl2 Medium
After 4 hrs incubation, monolayer cells did not show significant toxicity effects with
up to 20 µM ZnCl2 (See A in Figure 17). No significant differences were found in
metabolic activities of biopsy samples from different locations. Therefore, data were
combined for further analysis. There was no significant change of cell metabolic
activities between zinc and stromal medium immediately after loading (See B in
Figure 17). However, medium became acidic with a pH of 4.2 after 7 days of culture,
and the majority of cells were dead (See C,D in Figure 17). Additonally, scaffolds
had significantly lower metabolic activities after 7 days culture in medium with zinc
than 2hr after loading (See B in Figure 17). In contrast, after 7 days of culture in
stromal medium, cells on the collagen scaffold had significantly higher metabolic
activities. Based on these results, zinc was not used in induction medium.

	
  

75

	
  

Figure 17 Cytotoxicity of ZnCl2
Cells were cultured in stromal medium with different concentrations of ZnCl2
overnight and then stained with Alamar Blue for 4hr (A). Cells were loaded onto the
collagen scaffold, and metabolic activity (mean ± SEM, n=3) was measured
immediately after loading and 7 days (B). Construct was stained with calcein (green)
and ethidium bromise (red) and observed with fluorescent and (5x) (C) and confocal
laser microscopy (20x) (D). Columns with different letters are significantly different
from stromal control (P < 0.05). Columns with asterisks are significantly different
from 0d.
4.3.5 Growth Factor Medium
When collagen scaffolds were coated with Fn, the metabolic activity was significantly
higher than non-coated controls (See A in Figure 18). There were more cells apparent
with viability staining and confocal laser microscopy (See B in Figure 18). Based on
these results, COLI scaffolds were first incubated with Fn for 30 min before loading.
Additionally, no significant differences were found among biopsy samples from
different locations of the construct (1, 2, 3 cm from the top of the template), so data
were combined.
No significant differences were found in cell metabolic activity between
growth factor and stromal medium up to 21 days (See A in Figure 19). There was
significantly higher cell activity after 7 days of bioreactor culture for both groups, and
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cells were larger (See B in Figure 19). After 21 days of culture, more cells were
apparent in confocal laser and scanning electron images (Figures 20, 21), and
constructs had significantly higher activity than 7 and 14 days (See A in Figure 19).

Figure 18 Metabolic activity (mean ± SEM, n=6) of construct with Fn coating for cell
loading
Collagen scaffolds were soaked in Fn solution for 30 min before loading. After 2 hrs,
metabolic activity was measured for both Fn and control group. Samples were stained
with calcein (green) and EB (red), and observed by confocal microscope.

Figure 19 Metabolic activity (mean ± SEM, n=5) of canine ASC–COLI constructs
Canine ASC-COLI constructs were cultured in a perfusion bioreactor up to 21 days.
Metabolic activity was measured after 0, 7, 14 and 21 days of culture in
ligamentogenesis or stromal medium.
4.3.6 Collagen Deposition
Since Sirius red stains the collagen, staining was normalized to scaffold only (cultured
for the same period of time). Constructs in ligamentogenesis medium had higher
collagen than those cultured in stromal medium after 21 days of culture (Figure 22).
There was a slight increase in collagen content between 7 and 14 days in stromal
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group, and collagen content was significantly greater in both groups after 21 days of
culture compared to 7 days.

Figure 20 Confocal images of canine ASC-COLI constructs
Constructs were cultured in stromal (A-D) or ligamentogenesis (E-H) medium up to
21 days. Samples were collected after 7 (B,E), 14 (C,F) and 21 (D,G) days of culture.
Samples were stained with calcein (green, viable) and ethidium bromide (red,
nonviable), and observed with confocal laser scanning microscopy. Scale bar: 150
µm.

Figure 21 SEM images of canine ASC-COLI constructs
The ASCs (red arrows) – COLI constructs were cultured in ligamentogenesis (B-D) or
stromal (E-G) medium up to 21 days. Samples were collected after 7 (B,E), 14 (C,F)
and 21 (D,G) days of culture. Collagen scaffold is shown for comparison (A).
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Figure 22 Total collagen content (mean ± SEM, n=6) of canine ASC-COLI constructs
cultured in stromal or ligamentogenesis medium for 7, 14 or 21 days.
Scaffold was digested with pepsin and total collagen deposition was measured,
normalized to scaffold only, and determined on a standard curve. Columns with
different letters are significantly different from other time points within treatment
cohorts (P < 0.05). Columns with asterisks are significantly different from stromal
control within time points.
4.3.7 Pro-collagen Synthesis
The medium PINP levels were significantly higher in medium surrounding constructs
cultured in ligamentogenesis medium versus those in stromal medium after 7 and
21days of culture (Figure 23). Within cohorts, levels were significantly higher in the
ligamentogenesis medium group after 21 versus 7 and 14 days of culture, and in the
stromal medium group after 21 and 14 days versus 7 and 14 days of culture.
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Figure 23 Pro-collagen synthesis (mean ± SEM, n=4) of canine ASC/ColI scaffold
construct
Medium was collected at day 7, 14 and 21 after loading. Concentration of PINP was
measured using an ELISA kit. Columns with different letters are significantly
different from other time points within treatment cohorts (P < 0.05). Columns with
asterisks are significantly different from stromal control within time poitns.

	
  

79

	
  
4.3.8 Ligamentogenesis Target Gene Expression
In general, constructs cultured in ligamentogenesis medium had higher mRNA levels
of COLI, COLIII, TNMD, FN TNC, BGN and DCN than those cultured in stromal
medium (Figure 25). Additionally, mRNA levels of the genes were highest after 21
days of induction, followed by 14 and 7 days. The col1, TNC and TNMD expression
was significantly higher at day 21 compared to day 7.
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Figure 24 Fold change (mean ± SEM, n=4) of ligament target gene mRNA levels in
canine ASC/ColI scaffold constructs
Fold change of mRNA levels in the constructs cultured in ligament induction medium
relative to those in stromal medium for 7, 14 or 21 days. Columns with different
letters are significantly different from each other (P < 0.05).
4.4 Discussion
The ideal regenerated tissue will have cell proliferation, protein synthesis, deposition
of ECX and mechanical properties similar to the native tissue. Consistent with the
hypothesis, the collagen type I porous scaffold with PDS II suture supported IFP ASC
attachment, proliferation, ligament differentiation and collagen deposition when
cultured in ligamentogenosous induction medium.
The IFP was used as the MSC source in this study. Different cell sources have
been used in ligament tissue engineering such as MSCs and fibroblasts [330-333].
Previous work in the laboratory confirmed that, up to P3, MSCs from the IFP have
higher in vitro expansion, multipotentiality and progenitor immunophenotypes
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compared to those from joint capsular and CrCL synovium [233]. Other studies have
shown that rabbit BMSCs from iliac crest have higher proliferation and collagen
excretion than ACL and MCL fibroblasts [118]. Since orthotopic MSCs generally
have higher potential for tissue-specific cell differentiation than heterotopic cells, IFP
ASCs may be an optimal cell source for ACL tissue regeneration [167]. To optimize
cell attachment, the scaffold was coated with fibronection [140]. A relatively low cell
seeding density was used since the ACL is relatively hypocellular compared to other
tissues [334].
The scaffold material selection is also critical to provide similar physical and
mechanical properties, degradability, and structural integrity similar to the original
CrCL. The ideal pore diameter for soft tissue formation is around 200 – 250 µm [124].
Both PLLA and PGA are biocompatible materials approved by the FDA for clinical
applications [308, 309].

Both have been applied for ligament engineering with

promising short-term. However, in this study, these materials failed to maintain their
structure during long-time dynamic culture. Previous studies have also shown poor
tissue integration, poor abrasion resistance and fatigue on long-term impact [335, 336].
Further modifications in relative ratios and construct structure may help resolve some
of the problems observed [308].
Type I collagen is the major component of the CrCL. The scaffold used in this
study is commercially available and has been applied in orthopedic tissue
regeneration [316]. It possesses interconnected pores with an average diameter of 190
µm [337]. However, collagen alone is not durable enough for long-term application
[317, 318]. Compared to other absorbable sutures, PDS II has relatively higher tensile
strength and failure load [338]. Therefore, a PDS suture was used to constructs the
scaffold frame to mimic the orientation of the major bands of the native CrCL and to
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confer mechanical strength and durability to the scaffold. The template was also
constructed with implantation in mind. Since the structure must be secured to the
tibia and femur within bone tunnels, the construct has elongated suture ends covered
with COLI and ASCs to secure the graft and facilitate integration into bone.
Perfusion bioreactors have been shown to improve the efficiency of 3D tissue
engineering [334]. The custom-made chamber allowed homogenous cell distribution
and maintenance of the scaffold with a 45-degree turn at the midpoint. Different fluid
flow rates have been applied in perfusion bioreactors. Very-low flow rates (0.01
ml/min) have been used to achieve low shear stress and high cell viability [144, 339].
In contrast, high flow rates result in lower cell viability [334]. To provide optimal
distribution of cells, nutrients, oxygen and removal of wastes for orthopedic
applications, a fluid flow range from 0.2 to 1 ml/min has been suggested [334].
According to Haagen-Poisseuille equation, τ = 32µQ/πd3 (τ: shear stress; Q: flow rate;
d: diameter; µ: kinetic viscosity), shear stress is directly proportional to flow rate and
inversely proportional to vessel diameter [340]. Considering the relatively large
volume of the system, this study used the flow rate at 1 ml/min.
Though the exact cocktail to differentiate MSCs into ligament fibroblasts still
has yet to determined, several chemicals and growth factors have been identified.
Platelet-rich plasma has been widely applied for in vivo intraarticular CrCL repair and
regeneration [341]. However, high concentrations (10%) of PRP interfered with ASC
attachment to scaffold in this study based on the size of particles (3µm) in SEM
images. Zinc promotes ligamentous healing, and has been reported to stimulate MSC
proliferation and DNA synthesis [342].

However, in this study, it significantly

induced pH reduction and cell death at low concentrations. The results are consistent
to what have been found in acidithiobacillus caldus cells [343]. Growth factors like
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βFGF, TGFβ, PDGF, VEGF and IGF are reported to induce ligamentogenesis [344346].

A combination of βFGF and TGFβ were previously reported to induce

significantly higher COLI deposition and tissue strength through matrix synthesis in
human BMSCs than other formulations in vitro [345]. Previous studies also found
that TGFβ and PDGF cultured with rabbit BMSCs were in high concentrations during
the initial phases of CrCL healing, and were crucial for neo-tissue formation and
restoration of function both in vitro and in vivo [346, 347]. Lower serum was applied
in the induction medium since it achieved significant increase of COLI mRNA levels
compared to the stromal medium in vitro [345]. The medium described in this study
appeared to generate significant higher ligamentogenesis based on target gene
expression, collagen deposition and pro-collagen synthesis. The medium may prove
useful to generate viable grafts in vitro.
The mRNA data from this study suggests that constructs cultured in induction
medium had increased ligament target gene expression. Although there is no single
specific gene for ligamentogenesis, col I, col III, TNMD, TNC, BGN, DCN and FN
are all expressed in normal and healing CrCL [348-352]. Early stage markers, TNMD
and TNC, are necessary for cell proliferation and collagen fibril maturation [353, 354].
Collagen II and proteoglycans like BGN and DCN regulate assembly of collagen
fibrils at later stages of ligament development or repair [355-357]. Additionally, the
upregulation of TNC suggests ligament being mechanically stimulated, indicating
successful mechanical stimulation provided in the perfusion bioreactor [358]. The
significant increase of col I, TNMD and TNC with no change in col III, BGN and
DCN in this study is more consistent with a pattern of early stage ligament
development rather than repair.
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Regenerated tissues with MSCs have advantages over traditional therapies.
The MSCs from healthy and young donors may have advantages of generating neotissue as well as immunoregulatory effects, since the number and differentiation
potential of MSCs are interfered by diseased or aged conditions [51, 104, 167]. The
MSCs would not only differentiate into tissue-specific lineages, but also attract
bioactive factors to accelerate healing process without stimulating the host immune
response. This study designed a specific perfusion bioreactor system to regenerate a
viable canine CrCL graft with the native structure. Further MSC sorting with MSC
and immunogenic surface markers may generate a purer population that can be further
applied to grow the CrCL. Longer in vitro culture time in the induction medium may
also help ligamentogenesis and maturation of MSCs.

Additional studies should

include comparisons of CrCLs generated from ligamentogenesis or stromal medium
in rodent models. Even though this in vitro study cannot reflect in vivo characteristics
of the CrCL, it provides vital translational information of MSC in tissue engineering
to achieve better efficiency and efficacy after implantation in vivo.
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CHAPTER 5. CONCLUSIONS AND FURTHER STUDIES
This dissertation is focused on translational studies of adult multipotent stromal cells
(MSCs). Overall, MSC-mediated therapies are in the early stage of development.
Due to their apparent versatility, MSCs have been applied in over 100 human clinical
trials to treat various diseases and conditions.

Unfortunately, results have been

inconsistent and, in some cases, less than favorable..

It is clear that controlled

investigations are necessary in the field of adult MSCs. The International Society for
Cellular Therapy position has minimal standards to define human MSCs. A standard
definition of adult MSC in veterinary medicine is also needed. However, limited
technical resources like species-specific antibodies make this goal challenging. Major
contributions of the studies described in this dissertation are species specific
techniques to isolate and characterize canine and feline MSCs.
An efficient adipose derived multipotent stromal cell (ASC) isolation
technique was developed for the feline study. Using the technique, ASCs can be
harvested from limited tissue to avoid the need for significant tissue harvest from
one animal or to combine tissues from several animals. Use of tissues from one
animal may also lower risk of rejection.

Feline-specific induction medium was

designed and tested to confirm feline MSC multi-potentiality and to be used in future
feline tissue regeneration studies. Results of the study showed that feline ASCs are
only suitable for treatment or tissue engineering up to 3 passages in vitro. Evaluation
of the effects of cryopreservation showed that feline ASCs could be banked without
losing their expansion and differentiation capabilities. The MSC surface markers that
were validated in the study can be used to select MSCs from a heterogenous cell
isolate.
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The results from the canine intra-articular MSC study showed that adiposederived MSCs (ASCs) have the most promise for intraarticular application. Tissues
evaluated in the study are the three most popular MSC sources inside the stifle and the
results will be of interest to both surgeons and scientists. Considering IFP tissue is
often excised during stifle surgeries, it is a reasonable choice for cell isolation that
will not require specific tissue harvest. It is also possible that ASCs from IFP tissues
may be protected from intra-articular inflammation. The fact that ASCs maintain
their properties after cryopreservation may make it possible to use allogeneic ASCs
from normal stifle joints. The MSC phenotype was confirmed in this study and the
techniques can be used for unrelated canine MSC studies to benefit research and
clinical application.
The third part of this describes use of canine IFP ASCs, to regenerate cranial
cruciate ligament (CrCL) neotissues. It is possible that the viable structures can be
matured into grafts for clinical application or may serve as a template to promote
CrCL generation in vivo. The scaffold template may support both approaches to
CrCL repair.

For the study, custom scaffold templates were designed,

ligamentogenesis medium optimized for canine ACS ligament induction and a novel
bioreactor seeding and culture system designed and applied to grow constructs up to
21 days. Progressive tissue maturation was confirmed at various time points during
the culture period. Implantation of induced cells may have significant advantages
over naïve MSCs. This work is highly novel and may benefit both canine and human
patients that suffer from rupture of the major ligament in the stifle (knee) joint.
This dissertation provides critical information to translate MSC from the
laboratory to clinical application. Further studies may include purification of feline
MSCs with MSC and immunogenic surface markers, mechanical testing of CrCL
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generated in vitro, further maturation of CrCL with longer culture time and MSC
supplement in vitro and characterization and functional analysis of generated CrCL in
vivo.
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